EU Clinical Trials Register

Clinical trial results:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult subjects With Moderate to Severe Chronic Plaque Psoriasis

Summary

EudraCT number	2016-001891-31
Trial protocol	HU CZ PL
Global end of trial date	10 July 2017

Results information

Result version number	v2 (current)
This version publication date	12 December 2020
First version publication date	26 July 2018
Version creation reason	• Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review.

Trial information

Trial identification

Sponsor protocol code	PS0010

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02905006
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	UCB Biopharma SPRL
Sponsor organisation address	Allée de la Recherche 60, Brussels, Belgium, B-1070
Public contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com
Scientific contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 July 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	10 July 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the dose response of bimekizumab administered subcutaneously (sc) for 12 weeks in the treatment of participants with moderate to severe chronic plaque psoriasis.

Protection of trial subjects:

Patients were given the opportunity to discuss the study with the study doctor and ask questions before deciding to participate. The Study doctors asked about any problems patients had since the last visit, and what medications patients were taking. Routine safety blood and urine samples taken, electrocardiography (ECG), physical examinations and vital signs were taken, as well as questions about mental health were being asked to monitor the patient's safety.

Background therapy:

Topical medications
Participants continued to use topical moisturizers or emollients, bath oils, or oatmeal bath preparations for skin conditions during the study, as needed. Over-the-counter shampoos for the treatment of psoriasis of the scalp were also permitted. Participants who used prohibited topical medications were allowed to stay in the study but were counseled to not use them further. No other topical preparations were allowed in the 2 weeks before randomization or during the study unless medically required to treat an Adverse Event (AE).
Other medications
Participants who were already receiving an established non-steroidal anti-inflammatory drug (NSAID) regimen (at least 8 weeks prior to Baseline) and have been on a stable dose for at least 4 weeks prior to Baseline continued the use during the study. However, initiation of, or increase in dosage of, NSAIDs during the study (especially in participants with a history of gastrointestinal [GI] intolerance to NSAIDs or a history of GI ulceration) should have been done with caution. Intra-articular steroid injections for arthritis of the knee were allowed.
Participants who were already receiving an established anti-depressant regimen should have been on a stable dose of anti-depressant for 12 weeks prior to Baseline.

Evidence for comparator:

Not applicable

Actual start date of recruitment	25 August 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	11 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 39
Country: Number of subjects enrolled	Czechia: 22
Country: Number of subjects enrolled	Hungary: 18
Country: Number of subjects enrolled	Japan: 12

Country: Number of subjects enrolled	Poland: 115
Country: Number of subjects enrolled	United States: 44
Worldwide total number of subjects	250
EEA total number of subjects	155

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	228
From 65 to 84 years	22
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study started to enroll participants in August 2016 and concluded in July 2017.

Pre-assignment

Screening details:

The study included a 2-4 week Screening Period and a 12-week Treatment Period. Completed study was defined as completed the 12-week double-blind Treatment Period. After Treatment Period participants either enrolled in an extension study (PS0011) or entered a 20-week Safety Follow-Up Period. Participant Flow refers to the Randomized Set.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Monitor, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	PBO
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also be administered at Week 12 for all participants entering the open-label extension study.

Arm title	Bimekizumab 64 mg Q4W

Arm description:

Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.

Arm type	Experimental
Investigational medicinal product name	Bimekizumab
Investigational medicinal product code	UCB4940
Other name	UCB4940
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also administered at Week 12 for all participants entering the open-label extension study.

Arm title	Bimekizumab 160 mg Q4W

Arm description:

Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.

Arm type	Experimental
Investigational medicinal product name	Bimekizumab
Investigational medicinal product code	UCB4940
Other name	UCB4940
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also administered at Week 12 for all participants entering the open-label extension study.

Arm title	Bimekizumab 160 mg w/ LD Q4W

Arm description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.

Arm type	Experimental
Investigational medicinal product name	Bimekizumab
Investigational medicinal product code	UCB4940
Other name	UCB4940
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also administered at Week 12 for all participants entering the open-label extension study.

Arm title	Bimekizumab 320 mg Q4W

Arm description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.

Arm type	Experimental
Investigational medicinal product name	Bimekizumab
Investigational medicinal product code	UCB4940
Other name	UCB4940
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also administered at Week 12 for all participants entering the open-label extension study.

Arm title	Bimekizumab 480 mg Q4W

Arm description:

Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.

Arm type	Experimental
Investigational medicinal product name	Bimekizumab
Investigational medicinal product code	UCB4940
Other name	UCB4940
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

The study medication was administered in the clinic by study site staff as 3 subcutaneous (sc) injections. Suitable areas for sc injections were the lateral abdominal wall and upper outer thigh. During each dosing visit (Baseline, Week 4, and Week 8), each of the 3 injections were administered at a separate injection site. Study medication were also administered at Week 12 for all participants entering the open-label extension study.

Number of subjects in period 1	Placebo	Bimekizumab 64 mg Q4W	Bimekizumab 160 mg Q4W
Started	42	39	43
Completed Treatment period	37	36	38
Enrolled in extension study (PS0011)	38	35 [1]	39
Entered Safety Follow-up Period	4 [2]	4 [3]	4 [4]
Completed	37	36	38
Not completed	5	3	5
Positive for Tuberculosis	-	1	-
Consent withdrawn by subject	-	-	1
Lab withdrawal criterion met	-	1	2
Adverse event, non-fatal	1	1	1
Screening exclusion criteria met	1	-	-
Patient moved abroad	-	-	-
Subject positive for Hep B	-	-	1
Lost to follow-up	-	-	-
Patient randomized by mistake	-	-	-
Lack of efficacy	1	-	-
Protocol deviation	2	-	-

Number of subjects in period 1	Bimekizumab 160 mg w/ LD Q4W	Bimekizumab 320 mg Q4W	Bimekizumab 480 mg Q4W
Started	40	43	43
Completed Treatment period	34	40	39
Enrolled in extension study (PS0011)	38	42	40
Entered Safety Follow-up Period	2 [5]	1 [6]	3 [7]
Completed	34	40	39
Not completed	6	3	4
Positive for Tuberculosis	-	-	-
Consent withdrawn by subject	1	-	1
Lab withdrawal criterion met	2	2	1
Adverse event, non-fatal	1	-	1
Screening exclusion criteria met	-	-	-
Patient moved abroad	1	-	

Subject positive for Hep B	-	-	-
Lost to follow-up	1	1	-
Patient randomized by mistake	-	-	1
Lack of efficacy	-	-	-
Protocol deviation	-	-	-

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who enrolled in the extension study (PS0011).

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Number of participants at the milestones reflects those who entered a 20-week Safety Follow-Up Period.

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).	
Reporting group title	Bimekizumab 64 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 160 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 160 mg w/ LD Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 320 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 480 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.	

Reporting group values	Placebo	Bimekizumab 64 mg Q4W	Bimekizumab 160 mg Q4W
Number of subjects	42	39	43
Age categorical			
Units: Subjects			
<=18 years	0	1	0
Between 18 and 65 years	39	36	40
>=65 years	3	2	3
Age continuous			
Units: years			
arithmetic mean	46.7	44.2	43.4
standard deviation	± 12.3	± 13.8	± 12.4
Gender categorical			
Units: Subjects			
Female	17	19	11
Male	25	20	32

Reporting group values	Bimekizumab 160 mg w/ LD Q4W	Bimekizumab 320 mg Q4W	Bimekizumab 480 mg Q4W
Number of subjects	40	43	43
Age categorical			
Units: Subjects			
<=18 years	0	0	2
Between 18 and 65 years	35	39	36
>=65 years	5	4	5

Age continuous Units: years			
arithmetic mean	46.5	42.6	42.9
standard deviation	± 15.2	± 13.6	± 15.2
Gender categorical Units: Subjects			
Female	11	15	14
Male	29	28	29

Reporting group values	Total		
Number of subjects	250		
Age categorical Units: Subjects			
<=18 years	3		
Between 18 and 65 years	225		
>=65 years	22		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	87		
Male	163		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).	
Reporting group title	Bimekizumab 64 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 160 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 160 mg w/ LD Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 320 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.	
Reporting group title	Bimekizumab 480 mg Q4W
Reporting group description:	
Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.	
Subject analysis set title	Placebo (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).	
Subject analysis set title	Bimekizumab 64 mg Q4W (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.	
Subject analysis set title	Bimekizumab 160 mg Q4W (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.	
Subject analysis set title	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.	
Subject analysis set title	Bimekizumab 320 mg Q4W (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.	
Subject analysis set title	Bimekizumab 480 mg Q4W (FAS)
Subject analysis set type	Full analysis
Subject analysis set description:	
Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.	

Subject analysis set title	Placebo (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Pharmacokinetics Per-Protocol Set (PK-PPS).

Subject analysis set title	Bimekizumab 64 mg Q4W (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.

Subject analysis set title	Bimekizumab 160 mg Q4W (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.

Subject analysis set title	Bimekizumab 160 mg w/ LD Q4W (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.

Subject analysis set title	Bimekizumab 320 mg Q4W (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.

Subject analysis set title	Bimekizumab 480 mg Q4W (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.

Subject analysis set title	Placebo (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).

Subject analysis set title	Bimekizumab 64 mg Q4W (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg Q4W (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 320 mg Q4W (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 480 mg Q4W (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Placebo (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).

Subject analysis set title	Bimekizumab 64 mg Q4W (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg Q4W (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 320 mg Q4W (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Bimekizumab 480 mg Q4W (SS) Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.

Subject analysis set title	Placebo (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive Placebo during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	Bimekizumab 64 mg Q4W (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive 64 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg Q4W (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	Bimekizumab 320 mg Q4W (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive 320 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	Bimekizumab 480 mg Q4W (SS) Post-Treatment Period
Subject analysis set type	Safety analysis

Subject analysis set description:

At Week 12, participants who were randomized to receive 480 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Subject analysis set title	All participants (PK-PPS)
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.

Primary: Percentage of participants achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12

End point title	Percentage of participants achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12

End point description:

PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This scoring system averages the redness/thickness/scaliness of the psoriatic lesions and weights the resulting score by the area of skin involved. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness/thickness/scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness/thickness/scaliness of psoriatic skin lesions multiplied by the involved psoriasis area score and weighted by the percentage of the person's affected skin for the respective section. Min PASI score is 0=no disease, max score is 72=maximal disease.
The FAS consisted of all randomized participants who received at least 1 dose of medication and had a valid measurement of the primary efficacy at Baseline.

End point type	Primary

End point timeframe:
Week 12

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	0	46.2	67.4	75.0

End point values	Bimekizumab 320 mg Q4W (FAS)	Bimekizumab 480 mg Q4W (FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	79.1	72.1		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)
Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [1]
Method	Regression, Logistic

Notes:

[1] - P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [2]
Method	Regression, Logistic

Notes:

[2] - P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [3]
Method	Regression, Logistic

Notes:

[3] - P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.

Statistical analysis title	Statistical analysis 4
Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [4]
Method	Regression, Logistic

Notes:

[4] - P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.

Secondary: Percentage of participants with Investigator's Global Assessment (IGA) (Clear or Almost Clear with at least 2 category improvement from Baseline) response at Week 12

End point title	Percentage of participants with Investigator's Global Assessment (IGA) (Clear or Almost Clear with at least 2 category improvement from Baseline) response at Week 12

End point description:

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	4.8	51.3	74.4	75.0

End point values	Bimekizumab 320 mg Q4W	Bimekizumab 480 mg Q4W		

	(FAS)	(FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	86.0	76.7		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)
Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	21.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.51
upper limit	101.88

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	63.21
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.9
upper limit	309.83

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg w/ LD Q4W (FAS)
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	62.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.61
upper limit	308.29

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	130.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	24.5
upper limit	693.51

Statistical analysis title	Statistical analysis 5

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)

Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	69.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	14.07
upper limit	342.4

Secondary: Percentage of participants with Investigator's Global Assessment (IGA) (Clear or Almost Clear with at least 2 category improvement from Baseline) response at Week 8

End point title	Percentage of participants with Investigator's Global Assessment (IGA) (Clear or Almost Clear with at least 2 category improvement from Baseline) response at Week 8

End point description:

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.

End point type	Secondary

End point timeframe:

Week 8

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	4.8	46.2	62.8	77.5

End point values	Bimekizumab 320 mg Q4W (FAS)	Bimekizumab 480 mg Q4W (FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	86.0	72.1		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.	
Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)
Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	18.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.79
upper limit	87.76

Statistical analysis title	Statistical analysis 2
Statistical analysis description:	
Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.	
Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	39.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.19
upper limit	191.59

Statistical analysis title	Statistical analysis 3
Statistical analysis description:	
Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for	

treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg w/ LD Q4W (FAS)
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	77.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	15.19
upper limit	392.93

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	141.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.26
upper limit	767.72

Statistical analysis title	Statistical analysis 5

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	58.52

Confidence interval	
level	95 %
sides	2-sided
lower limit	11.89
upper limit	288

Secondary: Percentage of participants achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 8

End point title	Percentage of participants achieving a 90% or higher improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 8

End point description:

PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This scoring system averages the redness/thickness/scaliness of the psoriatic lesions and weights the resulting score by the area of skin involved. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness/thickness/scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness/thickness/scaliness of psoriatic skin lesions multiplied by the involved psoriasis area score and weighted by the percentage of the person's affected skin for the respective section. Min PASI score is 0=no disease, max score is 72=maximal disease.
The FAS consisted of all randomized participants who received at least 1 dose of medication and had a valid measurement of the primary efficacy at Baseline.

End point type	Secondary

End point timeframe:

Week 8

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	0	41.0	58.1	67.5

End point values	Bimekizumab 320 mg Q4W (FAS)	Bimekizumab 480 mg Q4W (FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	86.0	69.8		

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)
Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	Fisher exact

Notes:

[5] - The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [6]
Method	Fisher exact

Notes:

[6] - The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo (FAS) v Bimekizumab 160 mg w/ LD Q4W (FAS)
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [7]
Method	Fisher exact

Notes:

[7] - The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Statistical analysis title	Statistical analysis 4
Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [8]
Method	Fisher exact

Notes:

[8] - The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Statistical analysis title	Statistical analysis 5
Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [9]
Method	Fisher exact

Notes:

[9] - The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Secondary: Percentage of participants achieving a 75% or higher improvement in Psoriasis Area and Severity Index (PASI) score at Week 12

End point title	Percentage of participants achieving a 75% or higher improvement in Psoriasis Area and Severity Index (PASI) score at Week 12

End point description:

PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. This scoring system averages the redness/thickness/scaliness of the psoriatic lesions and weights the resulting score by the area of skin involved. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness/thickness/scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness/thickness/scaliness of psoriatic skin lesions multiplied by the involved psoriasis area score and weighted by the percentage of the person's affected skin for the respective section. Min PASI score is 0=no disease, max score is 72=maximal disease.
The FAS consisted of all randomized participants who received at least 1 dose of medication and had a valid measurement of the primary efficacy at Baseline.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	4.8	61.5	81.4	85.0

End point values	Bimekizumab 320 mg Q4W (FAS)	Bimekizumab 480 mg Q4W (FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	93.0	83.7		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)

Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	32.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.82
upper limit	156.38

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	94.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.54
upper limit	481.86

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg w/ LD Q4W (FAS)
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	117.66

Confidence interval	
level	95 %
sides	2-sided
lower limit	22.08
upper limit	626.89

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	280.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	44.06
upper limit	1789.24

Statistical analysis title	Statistical analysis 5

Statistical analysis description:

Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.

Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	107.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	20.82
upper limit	558.57

Secondary: Percentage of participants achieving a 100% improvement from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12

End point title	Percentage of participants achieving a 100% improvement

	from Baseline in Psoriasis Area and Severity Index (PASI) score at Week 12

End point description:

PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.
The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.

End point type	Secondary

End point timeframe:

Week 12

End point values	Placebo (FAS)	Bimekizumab 64 mg Q4W (FAS)	Bimekizumab 160 mg Q4W (FAS)	Bimekizumab 160 mg w/ LD Q4W (FAS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	0	28.2	27.9	60.0

End point values	Bimekizumab 320 mg Q4W (FAS)	Bimekizumab 480 mg Q4W (FAS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	55.8	48.8		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Comparison groups	Placebo (FAS) v Bimekizumab 64 mg Q4W (FAS)
Number of subjects included in analysis	81
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Fisher exact

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Fisher exact

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Comparison groups	Placebo (FAS) v Bimekizumab 160 mg w/ LD Q4W (FAS)
Number of subjects included in analysis	82
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Fisher exact

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Comparison groups	Placebo (FAS) v Bimekizumab 320 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Fisher exact

Statistical analysis title	Statistical analysis 5

Statistical analysis description:

The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.

Comparison groups	Placebo (FAS) v Bimekizumab 480 mg Q4W (FAS)
Number of subjects included in analysis	85
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Fisher exact

Secondary: Plasma concentrations of bimekizumab during the study

End point title	Plasma concentrations of bimekizumab during the study

End point description:

Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).
Values Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and CIs. Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point. The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.

Note 1: 999 is used as a placeholder for values below the level of detection since participants had no prior BKZ treatment (Baseline) and for values below the level of detection.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Bimekizumab 64 mg Q4W (PK-PPS)	Bimekizumab 160 mg Q4W (PK-PPS)	Bimekizumab 160 mg w/ LD Q4W (PK-PPS)	Bimekizumab 320 mg Q4W (PK-PPS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	42	40	43
Units: μg/mL				
geometric mean (confidence interval 95%)				
Baseline (39, 42, 40, 43, 43)	999 (999 to 999)	999 (999 to 999)	999 (999 to 999)	999 (999 to 999)
Week 1 (39, 42, 40, 43, 43)	4.4490 (3.7526 to 5.2746)	9.2481 (6.9779 to 12.2569)	20.7892 (14.9192 to 28.9688)	21.8622 (16.0624 to 29.7563)
Week 2 (39, 41, 39, 42, 42)	3.4704 (3.0167 to 3.9923)	8.6862 (7.5316 to 10.0179)	19.0428 (16.5381 to 21.9267)	19.0324 (16.8925 to 21.4434)
Week 4 (39, 41, 39, 41, 40)	2.1282 (1.8398 to 2.4617)	5.3751 (4.5233 to 6.3872)	11.2903 (9.4809 to 13.4450)	11.9194 (10.4503 to 13.5951)
Week 8 (38, 38, 37, 40, 40)	2.3069 (1.7780 to 2.9931)	7.1859 (5.3747 to 9.6075)	10.2208 (8.8561 to 11.7957)	16.3187 (13.9947 to 19.0285)
Week 12 (38, 38, 33, 40, 39)	2.3121 (1.6037 to 3.3335)	9.5278 (8.0614 to 11.2608)	10.2557 (8.6807 to 12.1165)	18.3166 (15.1652 to 22.1228)
SFU (4, 4, 2, 1, 3)	999 (999 to 999)	999 (999 to 999)	999 (999 to 999)	999 (999 to 999)

End point values	Bimekizumab 480 mg Q4W (PK-PPS)			
Subject group type	Subject analysis set			
Number of subjects analysed	43			
Units: μg/mL				

geometric mean (confidence interval 95%)				
Baseline (39, 42, 40, 43, 43)	999 (999 to 999)			
Week 1 (39, 42, 40, 43, 43)	31.8019 (23.3488 to 43.3154)			
Week 2 (39, 41, 39, 42, 42)	27.5641 (23.8485 to 31.8586)			
Week 4 (39, 41, 39, 41, 40)	17.1811 (14.7612 to 19.9977)			
Week 8 (38, 38, 37, 40, 40)	23.3285 (19.8863 to 27.3665)			
Week 12 (38, 38, 33, 40, 39)	28.0908 (23.2463 to 33.9448)			
SFU (4, 4, 2, 1, 3)	0.5165 (0.0032 to 84.5222)			

Statistical analyses

No statistical analyses for this end point

Secondary: Population PK (apparent total clearance (CL/F)) of bimekizumab

End point title	Population PK (apparent total clearance (CL/F)) of bimekizumab

End point description:

The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

End point values	All participants (PK-PPS)			
Subject group type	Subject analysis set			
Number of subjects analysed	249			
Units: L/Day				
geometric mean (geometric coefficient of variation)	0.362 (± 41.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Population PK (apparent volume of distribution (V/F)) of bimekizumab

End point title	Population PK (apparent volume of distribution (V/F)) of bimekizumab

End point description:

The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

End point values	All participants (PK-PPS)			
Subject group type	Subject analysis set			
Number of subjects analysed	249			
Units: liters				
geometric mean (geometric coefficient of variation)	11.5 (± 146)			

Statistical analyses

No statistical analyses for this end point

Secondary: Concentration of bimekizumab leading to 50% of maximum effect (EC50)

End point title	Concentration of bimekizumab leading to 50% of maximum effect (EC50)

End point description:

The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.
It was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.
The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. EC50 was estimated based on all available data and cannot be derived for each treatment arm.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)

End point values	All participants (PK-PPS)			
Subject group type	Subject analysis set			
Number of subjects analysed	249			
Units: µg/mL				
geometric mean (geometric coefficient of variation)	0.55 (± 126)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with a positive anti-bimekizumab antibody (AbAb) status prior to study treatment

End point title	Percentage of participants with a positive anti-bimekizumab antibody (AbAb) status prior to study treatment

End point description:

Antibody positive status prior study treatment was defined as having an antibody level greater than (>) 28.5% at Baseline (Week 0).
The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.

End point type	Secondary

End point timeframe:

Baseline (Week 0)

End point values	Placebo (PK-PPS)	Bimekizumab 64 mg Q4W (PK-PPS)	Bimekizumab 160 mg Q4W (PK-PPS)	Bimekizumab 160 mg w/ LD Q4W (PK-PPS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: percentage of participants				
number (not applicable)	0	0	0	2.5

End point values	Bimekizumab 320 mg Q4W (PK-PPS)	Bimekizumab 480 mg Q4W (PK-PPS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with an overall positive anti-bimekizumab antibody (AbAb) status following study treatment

End point title	Percentage of participants with an overall positive anti-bimekizumab antibody (AbAb) status following study treatment

End point description:

Overall antibody positive was defined as having a value of > 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.
The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.

End point type	Secondary

End point timeframe:

From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)

End point values	Placebo (PK-PPS)	Bimekizumab 64 mg Q4W (PK-PPS)	Bimekizumab 160 mg Q4W (PK-PPS)	Bimekizumab 160 mg w/ LD Q4W (PK-PPS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: percentage of participants				
number (not applicable)	0	10.3	4.8	5.0

End point values	Bimekizumab 320 mg Q4W (PK-PPS)	Bimekizumab 480 mg Q4W (PK-PPS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with at least one adverse event (AE) during the study

End point title	Percentage of participants with at least one adverse event (AE) during the study

End point description:

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

End point type	Secondary

End point timeframe:

From Screening to End of Safety Follow-up (up to Week 32)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	38.1	76.9	55.8	65.0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	60.5	60.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with at least one adverse event (AE) during the study by severity

End point title	Percentage of participants with at least one adverse event (AE) during the study by severity

End point description:

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

End point type	Secondary

End point timeframe:

From Screening to End of Safety Follow-up (up to Week 32)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)				
Mild	11.9	43.6	27.9	22.5
Moderate	26.2	30.8	27.9	40.0
Severe	0	2.6	0	2.5

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)				
Mild	39.5	44.2		
Moderate	20.9	11.6		
Severe	0	4.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (platelets)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (platelets)

End point description:

Platelets was measured in number of platelets per liter (10^9/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: 10^9 platelets per liter				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	12.1 (± 34.7)	3.2 (± 21.0)	-4.6 (± 30.8)	-14.0 (± 30.8)
Week 2 (41, 39, 40, 39, 41, 41)	6.4 (± 37.8)	-8.6 (± 26.8)	-5.6 (± 36.4)	-8.9 (± 27.8)
Week 4 (41, 39, 41, 39, 40, 40)	-0.1 (± 32.0)	-5.8 (± 28.3)	-8.6 (± 40.1)	-11.4 (± 21.8)
Week 6 (40, 38, 38, 36, 39, 40)	5.6 (± 47.5)	-5.2 (± 26.3)	-13.6 (± 34.3)	-5.6 (± 30.3)
Week 8 (39, 37, 38, 35, 40, 40)	6.9 (± 37.6)	-2.3 (± 44.7)	-6.1 (± 43.7)	6.3 (± 35.6)
Week 12 (39, 38, 37, 35, 40, 38)	2.8 (± 36.7)	-6.0 (± 36.2)	-13.2 (± 40.1)	-3.6 (± 37.5)
SFU (4, 4, 4, 2, 1, 3)	14.8 (± 33.3)	-30.3 (± 71.6)	7.8 (± 20.0)	-33.0 (± 31.1)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: 10^9 platelets per liter				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	3.5 (± 25.2)	-0.1 (± 35.0)		
Week 2 (41, 39, 40, 39, 41, 41)	7.8 (± 31.2)	-3.9 (± 41.8)		
Week 4 (41, 39, 41, 39, 40, 40)	-7.0 (± 28.9)	-7.5 (± 36.8)		
Week 6 (40, 38, 38, 36, 39, 40)	-0.3 (± 44.0)	-7.6 (± 37.3)		
Week 8 (39, 37, 38, 35, 40, 40)	0.7 (± 39.5)	-4.7 (± 36.4)		
Week 12 (39, 38, 37, 35, 40, 38)	-5.4 (± 36.1)	-5.5 (± 38.8)		
SFU (4, 4, 4, 2, 1, 3)	39.0 (± 999)	39.3 (± 27.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular hemoglobin (HGB) concentration, hemoglobin)

End point description:

Erythrocytes mean corpuscular hemoglobin concentration (MCHC) and hemoglobin were measured in grams per liter (g/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: g/L				
arithmetic mean (standard deviation)				
MCHC Week 1 (42, 39, 42, 40, 43, 42)	0.1 (± 8.1)	-2.0 (± 10.3)	-0.3 (± 8.8)	-1.0 (± 11.6)
MCHC Week 2 (41, 39, 41, 39, 41, 41)	0.1 (± 7.9)	1.1 (± 6.6)	1.6 (± 9.4)	-0.3 (± 9.8)
MCHC Week 4 (41, 39, 41, 39, 41, 40)	-0.2 (± 9.1)	0.2 (± 8.3)	-0.1 (± 9.9)	-2.9 (± 6.3)
MCHC Week 6 (40, 38, 38, 37, 40, 40)	-2.5 (± 11.0)	-1.7 (± 8.6)	-0.5 (± 9.4)	-2.9 (± 7.0)
MCHC Week 8 (39, 37, 38, 35, 40, 40)	-2.2 (± 8.0)	-1.4 (± 12.7)	0.3 (± 10.3)	-2.5 (± 7.9)
MCHC Week 12 (39, 38, 37, 35, 40, 38)	-6.3 (± 12.5)	-2.2 (± 14.7)	-1.6 (± 9.1)	-4.5 (± 10.1)
MCHC Week SFU (4, 4, 4, 2, 1, 3)	-12.5 (± 11.0)	5.3 (± 26.2)	-5.5 (± 10.6)	-9.5 (± 7.8)
Hemoglobin Week 1 (42, 39, 42, 40, 43, 42)	-2.9 (± 7.3)	0.1 (± 6.1)	1.0 (± 6.8)	-2.6 (± 5.2)
Hemoglobin Week 2 (41, 39, 41, 39, 41, 41)	-3.0 (± 6.7)	0.5 (± 5.3)	0.6 (± 6.0)	-1.5 (± 7.5)
Hemoglobin Week 4 (41, 39, 41, 39, 41, 40)	-2.9 (± 8.2)	0.8 (± 6.1)	-0.9 (± 6.2)	-2.1 (± 5.9)
Hemoglobin Week 6 (40, 38, 38, 37, 40, 40)	-2.4 (± 7.8)	0.7 (± 6.3)	-0.3 (± 6.6)	-1.2 (± 4.8)
Hemoglobin Week 8 (39, 37, 38, 35, 40, 40)	-2.7 (± 8.0)	1.1 (± 7.6)	0.8 (± 7.1)	-0.6 (± 7.5)
Hemoglobin Week 12 (39, 38, 37, 35, 40, 38)	-1.8 (± 9.1)	3.2 (± 9.6)	-0.1 (± 8.1)	-1.0 (± 8.5)
Hemoglobin SFU (4, 4, 4, 2, 1, 3)	-4.8 (± 7.4)	7.8 (± 31.0)	-6.5 (± 4.7)	-8.5 (± 2.1)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: g/L				
arithmetic mean (standard deviation)				
MCHC Week 1 (42, 39, 42, 40, 43, 42)	0.5 (± 8.6)	0.3 (± 8.1)		
MCHC Week 2 (41, 39, 41, 39, 41, 41)	2.6 (± 7.9)	1.8 (± 8.8)		
MCHC Week 4 (41, 39, 41, 39, 41, 40)	0.1 (± 8.0)	-0.4 (± 11.7)		
MCHC Week 6 (40, 38, 38, 37, 40, 40)	-0.5 (± 7.8)	-1.3 (± 8.9)		
MCHC Week 8 (39, 37, 38, 35, 40, 40)	-2.1 (± 9.2)	-2.9 (± 9.2)		
MCHC Week 12 (39, 38, 37, 35, 40, 38)	-2.0 (± 12.7)	-3.6 (± 13.7)		
MCHC Week SFU (4, 4, 4, 2, 1, 3)	-2.0 (± 999)	-22.0 (± 18.0)		
Hemoglobin Week 1 (42, 39, 42, 40, 43, 42)	-1.0 (± 7.0)	-0.8 (± 5.0)		
Hemoglobin Week 2 (41, 39, 41, 39, 41, 41)	-1.1 (± 7.0)	0.5 (± 6.6)		

Hemoglobin Week 4 (41, 39, 41, 39, 41, 40)	-1.8 (± 8.7)	-0.4 (± 6.3)
Hemoglobin Week 6 (40, 38, 38, 37, 40, 40)	-2.1 (± 8.4)	0.9 (± 6.3)
Hemoglobin Week 8 (39, 37, 38, 35, 40, 40)	-1.8 (± 8.1)	0.9 (± 6.5)
Hemoglobin Week 12 (39, 38, 37, 35, 40, 38)	-1.2 (± 9.3)	0.3 (± 7.1)
Hemoglobin SFU (4, 4, 4, 2, 1, 3)	6.0 (± 999)	-6.7 (± 11.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular hemoglobin (HGB))

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular hemoglobin (HGB))

End point description:

Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: picograms (pg)				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.09 (± 0.57)	-0.01 (± 0.56)	-0.10 (± 0.55)	0.07 (± 0.51)
Week 2 (41, 39, 41, 39, 41, 41)	-0.04 (± 0.59)	0.04 (± 0.54)	0.05 (± 0.49)	0.10 (± 0.78)
Week 4 (41, 39, 41, 39, 41, 40)	-0.07 (± 0.66)	0.10 (± 0.84)	-0.07 (± 0.63)	-0.01 (± 0.42)
Week 6 (40, 38, 38, 37, 40, 40)	-0.17 (± 0.64)	-0.09 (± 0.84)	-0.16 (± 0.61)	-0.11 (± 0.47)
Week 8 (39, 37, 38, 35, 40, 40)	-0.19 (± 0.64)	0.09 (± 1.09)	-0.16 (± 1.10)	-0.16 (± 0.64)
Week 12 (39, 38, 37, 35, 40, 38)	-0.34 (± 0.71)	0.09 (± 1.53)	-0.08 (± 0.58)	-0.14 (± 0.66)
SFU (4, 4, 4, 2, 1, 3)	-0.33 (± 0.79)	2.93 (± 6.66)	-0.15 (± 0.17)	-0.55 (± 0.78)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: picograms (pg)				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.09 (± 0.87)	0.00 (± 0.53)		
Week 2 (41, 39, 41, 39, 41, 41)	-0.03 (± 0.60)	0.14 (± 0.54)		
Week 4 (41, 39, 41, 39, 41, 40)	-0.10 (± 0.68)	0.04 (± 0.50)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.12 (± 0.84)	-0.04 (± 0.60)		
Week 8 (39, 37, 38, 35, 40, 40)	-0.26 (± 0.99)	-0.16 (± 0.53)		
Week 12 (39, 38, 37, 35, 40, 38)	-0.09 (± 1.14)	-0.16 (± 0.67)		
SFU (4, 4, 4, 2, 1, 3)	0.70 (± 999)	-0.60 (± 1.10)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular volume)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes mean corpuscular volume)

End point description:

Erythrocytes mean corpuscular volume was measured in femtolitres (fL).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: femtolitres (fL)				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.35 (± 1.55)	0.52 (± 2.29)	-0.25 (± 1.64)	0.51 (± 2.63)
Week 2 (41, 39, 41, 39, 41, 41)	-0.14 (± 1.65)	-0.16 (± 1.31)	-0.33 (± 1.96)	0.31 (± 1.32)
Week 4 (41, 39, 41, 39, 41, 40)	-0.11 (± 1.60)	0.23 (± 1.89)	-0.25 (± 1.81)	0.67 (± 1.76)
Week 6 (40, 38, 38, 37, 40, 40)	0.20 (± 2.84)	0.14 (± 2.47)	-0.29 (± 1.90)	0.39 (± 1.79)
Week 8 (39, 37, 38, 35, 40, 40)	0.05 (± 2.11)	0.71 (± 2.88)	-0.54 (± 2.57)	0.16 (± 2.57)
Week 12 (39, 38, 37, 35, 40, 38)	0.76 (± 3.81)	0.87 (± 3.23)	0.17 (± 2.39)	0.78 (± 2.55)

SFU (4, 4, 4, 2, 1, 3)	2.58 (± 5.10)	7.80 (± 14.07)	0.90 (± 2.38)	0.85 (± 0.35)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: femtolitres (fL)				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.23 (± 2.14)	-0.04 (± 1.37)		
Week 2 (41, 39, 41, 39, 41, 41)	-0.64 (± 1.40)	-0.05 (± 1.60)		
Week 4 (41, 39, 41, 39, 41, 40)	-0.10 (± 1.64)	0.22 (± 2.87)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.02 (± 1.92)	0.25 (± 1.85)		
Week 8 (39, 37, 38, 35, 40, 40)	-0.02 (± 2.29)	0.36 (± 2.37)		
Week 12 (39, 38, 37, 35, 40, 38)	0.47 (± 2.88)	0.51 (± 3.89)		
SFU (4, 4, 4, 2, 1, 3)	2.80 (± 999)	4.87 (± 8.46)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (erythrocytes)

End point description:

Erythrocytes was measured in number of red blood cells per liter (10^{12}/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: 10^{12} red blood cells per liter				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.081 (± 0.282)	0.004 (± 0.213)	0.047 (± 0.238)	-0.095 (± 0.184)

Week 2 (41, 39, 41, 39, 41, 41)	-0.088 (± 0.220)	0.010 (± 0.193)	0.014 (± 0.215)	-0.060 (± 0.282)
Week 4 (41, 39, 41, 39, 41, 40)	-0.085 (± 0.274)	0.019 (± 0.217)	-0.018 (± 0.193)	-0.066 (± 0.215)
Week 6 (40, 38, 38, 37, 40, 40)	-0.053 (± 0.277)	0.038 (± 0.218)	0.011 (± 0.243)	-0.019 (± 0.145)
Week 8 (39, 37, 38, 35, 40, 40)	-0.062 (± 0.320)	0.022 (± 0.245)	0.048 (± 0.219)	0.009 (± 0.224)
Week 12 (39, 38, 37, 35, 40, 38)	-0.007 (± 0.314)	0.092 (± 0.258)	0.011 (± 0.271)	-0.005 (± 0.297)
SFU (4, 4, 4, 2, 1, 3)	-0.090 (± 0.346)	-0.135 (± 0.184)	-0.195 (± 0.165)	-0.215 (± 0.035)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: 10^12 red blood cells per liter				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.029 (± 0.259)	-0.026 (± 0.178)		
Week 2 (41, 39, 41, 39, 41, 41)	-0.041 (± 0.231)	-0.001 (± 0.232)		
Week 4 (41, 39, 41, 39, 41, 40)	-0.053 (± 0.281)	-0.015 (± 0.216)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.060 (± 0.278)	0.035 (± 0.224)		
Week 8 (39, 37, 38, 35, 40, 40)	-0.028 (± 0.240)	0.056 (± 0.238)		
Week 12 (39, 38, 37, 35, 40, 38)	-0.036 (± 0.297)	0.039 (± 0.228)		
SFU (4, 4, 4, 2, 1, 3)	0.080 (± 999)	-0.123 (± 0.491)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (hematocrit)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (hematocrit)

End point description:

Hematocrit was measured in volume percentage (%) of red blood cells in blood.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: volume % of red blood cells				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.88 (± 2.49)	0.27 (± 2.07)	0.33 (± 2.31)	-0.58 (± 2.14)
Week 2 (41, 39, 41, 39, 41, 41)	-0.86 (± 2.02)	0.00 (± 1.65)	-0.04 (± 2.15)	-0.42 (± 2.61)
Week 4 (41, 39, 41, 39, 41, 40)	-0.81 (± 2.40)	0.24 (± 2.07)	-0.26 (± 1.86)	-0.26 (± 1.80)
Week 6 (40, 38, 38, 37, 40, 40)	-0.33 (± 2.46)	0.41 (± 1.88)	-0.04 (± 2.18)	0.02 (± 1.73)
Week 8 (39, 37, 38, 35, 40, 40)	-0.52 (± 2.37)	0.55 (± 2.51)	0.18 (± 1.84)	0.14 (± 2.61)
Week 12 (39, 38, 37, 35, 40, 38)	0.32 (± 2.87)	1.25 (± 2.29)	0.18 (± 2.57)	0.30 (± 2.99)
SFU (4, 4, 4, 2, 1, 3)	0.20 (± 1.44)	1.98 (± 6.92)	-1.20 (± 1.90)	-1.50 (± 0.14)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: volume % of red blood cells				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 42)	-0.36 (± 2.31)	-0.23 (± 1.62)		
Week 2 (41, 39, 41, 39, 41, 41)	-0.65 (± 2.09)	-0.02 (± 2.03)		
Week 4 (41, 39, 41, 39, 41, 40)	-0.48 (± 2.57)	-0.03 (± 2.02)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.51 (± 2.59)	0.44 (± 1.90)		
Week 8 (39, 37, 38, 35, 40, 40)	-0.22 (± 2.46)	0.67 (± 2.03)		
Week 12 (39, 38, 37, 35, 40, 38)	-0.05 (± 2.75)	0.59 (± 2.02)		
SFU (4, 4, 4, 2, 1, 3)	2.10 (± 999)	1.00 (± 0.85)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in hematology parameters (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

End point title	Change from Baseline until Safety Follow-up Visit in hematology parameters (basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils)

End point description:

Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10^9/L).

The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	41	40
Units: 10^9 white blood cells per liter				
arithmetic mean (standard deviation)				
Basophils Week 1 (42, 39, 41, 40, 43, 42)	0.01 (± 0.03)	0.01 (± 0.03)	0.00 (± 0.03)	0.01 (± 0.03)
Basophils Week 2 (41, 38, 41, 39, 40, 41)	0.00 (± 0.02)	0.00 (± 0.04)	0.01 (± 0.04)	0.01 (± 0.04)
Basophils Week 4 (41, 39, 41, 39, 41, 40)	0.00 (± 0.03)	0.00 (± 0.05)	0.00 (± 0.03)	0.01 (± 0.02)
Basophils Week 6 (40, 38, 38, 36, 40, 40)	0.01 (± 0.03)	0.00 (± 0.04)	0.00 (± 0.04)	0.01 (± 0.02)
Basophils Week 8 (39, 37, 37, 34, 40, 40)	0.00 (± 0.04)	-0.01 (± 0.04)	0.02 (± 0.01)	0.00 (± 0.00)
Basophils Week 12 (38, 38, 37, 34, 40, 38)	0.00 (± 0.03)	0.00 (± 0.04)	0.01 (± 0.03)	0.00 (± 0.02)
Basophils SFU (4, 4, 4, 2, 1, 3)	0.03 (± 0.05)	-0.03 (± 0.05)	0.00 (± 0.00)	0.00 (± 0.00)
Eosinophils Week 1 (42, 39, 43, 40, 43, 42)	0.02 (± 0.06)	0.02 (± 0.12)	0.01 (± 0.07)	0.04 (± 0.10)
Eosinophils Week 2 (41, 38, 41, 39, 40, 41)	0.02 (± 0.08)	0.04 (± 0.26)	0.00 (± 0.08)	0.05 (± 0.11)
Eosinophils Week 4 (41, 39, 41, 39, 41, 40)	0.03 (± 0.09)	0.04 (± 0.26)	0.01 (± 0.08)	0.02 (± 0.11)
Eosinophils Week 6 (40, 38, 38, 36, 40, 40)	0.04 (± 0.10)	0.02 (± 0.19)	0.00 (± 0.08)	0.01 (± 0.09)
Eosinophils Week 8 (39, 37, 37, 34, 40, 40)	0.01 (± 0.09)	0.01 (± 0.18)	0.01 (± 0.08)	0.04 (± 0.17)
Eosinophils Week 12 (38, 38, 37, 34, 40, 38)	0.02 (± 0.09)	0.03 (± 0.22)	0.00 (± 0.09)	0.00 (± 0.08)
Eosinophils SFU (4, 4, 4, 2, 1, 3)	0.05 (± 0.06)	0.08 (± 0.10)	0.10 (± 0.00)	0.00 (± 0.00)
Leukocytes Week 1 (42, 39, 42, 40, 43, 42)	0.16 (± 1.30)	-0.59 (± 1.34)	-0.15 (± 1.43)	-0.63 (± 1.82)
Leukocytes Week 2 (41, 38, 41, 39, 40, 41)	0.18 (± 1.36)	-0.56 (± 1.31)	-0.22 (± 1.43)	-0.42 (± 1.34)
Leukocytes Week 4 (41, 39, 41, 39, 41, 40)	0.17 (± 1.51)	-0.36 (± 1.31)	-0.23 (± 1.38)	-0.54 (± 1.14)
Leukocytes Week 6 (40, 38, 38, 37, 40, 40)	-0.22 (± 1.25)	-0.50 (± 1.95)	-0.47 (± 1.49)	-0.57 (± 1.34)
Leukocytes Week 8 (39, 37, 38, 35, 40, 40)	-0.10 (± 1.34)	-0.67 (± 1.55)	-0.24 (± 1.94)	-0.37 (± 1.55)
Leukocytes Week 12 (39, 38, 37, 34, 40, 38)	0.00 (± 1.37)	-0.28 (± 1.68)	-0.47 (± 1.67)	-0.51 (± 1.41)

Leukocytes SFU (4, 4, 4, 2, 1, 3)	-0.05 (± 0.98)	1.15 (± 2.54)	0.95 (± 1.43)	-0.65 (± 0.78)
Lymphocytes Week 1 (42, 39, 41, 40, 43, 42)	0.12 (± 0.36)	-0.05 (± 0.30)	0.15 (± 0.42)	0.13 (± 0.34)
Lymphocytes Week 2 (41, 38, 41, 39, 40, 41)	0.08 (± 0.32)	-0.11 (± 0.30)	0.09 (± 0.34)	0.09 (± 0.40)
Lymphocytes Week 4 (41, 39, 41, 39, 41, 40)	0.06 (± 0.40)	-0.04 (± 0.33)	0.15 (± 0.43)	0.08 (± 0.42)
Lymphocytes Week 6 (40, 38, 38, 36, 40, 40)	0.08 (± 0.46)	-0.08 (± 0.43)	0.03 (± 0.31)	0.04 (± 0.43)
Lymphocytes Week 8 (39, 37, 37, 34, 40, 40)	0.02 (± 0.37)	-0.04 (± 0.31)	0.09 (± 0.40)	0.11 (± 0.33)
Lymphocytes Week 12 (38, 38, 37, 34, 40, 38)	0.08 (± 0.38)	0.01 (± 0.35)	0.06 (± 0.38)	0.07 (± 0.48)
Lymphocytes SFU (4, 4, 4, 2, 1, 3)	0.25 (± 0.24)	0.25 (± 0.40)	0.23 (± 0.19)	0.25 (± 0.21)
Monocytes Week 1 (42, 39, 41, 40, 43, 42)	0.02 (± 0.16)	-0.01 (± 0.12)	0.02 (± 0.15)	0.02 (± 0.11)
Monocytes Week 2 (41, 38, 41, 39, 40, 41)	0.00 (± 0.14)	-0.04 (± 0.13)	0.00 (± 0.14)	0.04 (± 0.15)
Monocytes Week 4 (41, 39, 41, 39, 41, 40)	0.03 (± 0.16)	-0.01 (± 0.11)	0.01 (± 0.15)	0.03 (± 0.13)
Monocytes Week 6 (40, 38, 38, 36, 40, 40)	0.01 (± 0.15)	-0.01 (± 0.18)	0.02 (± 0.15)	0.00 (± 0.11)
Monocytes Week 8 (39, 37, 37, 34, 40, 40)	-0.02 (± 0.15)	-0.03 (± 0.11)	0.00 (± 0.16)	-0.01 (± 0.14)
Monocytes Week 12 (38, 38, 37, 34, 40, 38)	0.01 (± 0.16)	0.00 (± 0.14)	-0.02 (± 0.15)	-0.01 (± 0.18)
Monocytes SFU (4, 4, 4, 2, 1, 3)	0.10 (± 0.22)	0.10 (± 0.22)	0.03 (± 0.10)	0.00 (± 0.00)
Neutrophils Week 1 (42, 39, 41, 40, 43, 42)	-0.02 (± 1.16)	-0.55 (± 1.12)	-0.32 (± 1.25)	-0.81 (± 1.81)
Neutrophils Week 2 (41, 38, 41, 39, 40, 41)	0.09 (± 1.29)	-0.43 (± 1.05)	-0.31 (± 1.33)	-0.59 (± 1.09)
Neutrophils Week 4 (41, 39, 41, 39, 41, 40)	0.04 (± 1.30)	-0.35 (± 1.07)	-0.39 (± 1.31)	-0.68 (± 1.02)
Neutrophils Week 6 (40, 38, 38, 36, 40, 40)	-0.36 (± 0.98)	-0.43 (± 1.64)	-0.49 (± 1.38)	-0.54 (± 1.16)
Neutrophils Week 8 (39, 37, 37, 34, 40, 40)	-0.13 (± 1.18)	-0.61 (± 1.40)	-0.34 (± 1.72)	-0.57 (± 1.28)
Neutrophils Week 12 (38, 38, 37, 34, 40, 38)	-0.11 (± 1.17)	-0.33 (± 1.50)	-0.49 (± 1.50)	-0.57 (± 1.20)
Neutrophils SFU (4, 4, 4, 2, 1, 3)	-0.45 (± 0.79)	0.75 (± 1.88)	0.65 (± 1.20)	-0.95 (± 0.49)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	42		
Units: 10^9 white blood cells per liter				
arithmetic mean (standard deviation)				
Basophils Week 1 (42, 39, 41, 40, 43, 42)	0.00 (± 0.04)	0.01 (± 0.03)		
Basophils Week 2 (41, 38, 41, 39, 40, 41)	0.01 (± 0.04)	0.00 (± 0.03)		
Basophils Week 4 (41, 39, 41, 39, 41, 40)	0.01 (± 0.05)	0.00 (± 0.04)		
Basophils Week 6 (40, 38, 38, 36, 40, 40)	0.00 (± 0.04)	0.00 (± 0.04)		

Basophils Week 8 (39, 37, 37, 34, 40, 40)	0.02 (± 0.04)	0.00 (± 0.05)
Basophils Week 12 (38, 38, 37, 34, 40, 38)	0.01 (± 0.04)	0.00 (± 0.04)
Basophils SFU (4, 4, 4, 2, 1, 3)	0.00 (± 999)	0.03 (± 0.06)
Eosinophils Week 1 (42, 39, 43, 40, 43, 42)	0.02 (± 0.11)	-0.02 (± 0.12)
Eosinophils Week 2 (41, 38, 41, 39, 40, 41)	0.00 (± 0.11)	0.01 (± 0.11)
Eosinophils Week 4 (41, 39, 41, 39, 41, 40)	0.03 (± 0.09)	0.00 (± 0.18)
Eosinophils Week 6 (40, 38, 38, 36, 40, 40)	0.05 (± 0.16)	-0.01 (± 0.17)
Eosinophils Week 8 (39, 37, 37, 34, 40, 40)	0.05 (± 0.18)	-0.03 (± 0.16)
Eosinophils Week 12 (38, 38, 37, 34, 40, 38)	0.03 (± 0.13)	-0.03 (± 0.11)
Eosinophils SFU (4, 4, 4, 2, 1, 3)	-0.10 (± 999)	0.07 (± 0.06)
Leukocytes Week 1 (42, 39, 42, 40, 43, 42)	-0.19 (± 1.51)	-0.48 (± 0.90)
Leukocytes Week 2 (41, 38, 41, 39, 40, 41)	-0.31 (± 1.80)	-0.46 (± 1.29)
Leukocytes Week 4 (41, 39, 41, 39, 41, 40)	-0.36 (± 1.73)	-0.34 (± 1.24)
Leukocytes Week 6 (40, 38, 38, 37, 40, 40)	-0.45 (± 2.02)	-0.45 (± 1.12)
Leukocytes Week 8 (39, 37, 38, 35, 40, 40)	-0.30 (± 1.76)	-0.45 (± 0.87)
Leukocytes Week 12 (39, 38, 37, 34, 40, 38)	-0.50 (± 1.44)	-0.48 (± 1.09)
Leukocytes SFU (4, 4, 4, 2, 1, 3)	0.20 (± 999)	0.30 (± 0.40)
Lymphocytes Week 1 (42, 39, 41, 40, 43, 42)	0.14 (± 0.46)	0.00 (± 0.45)
Lymphocytes Week 2 (41, 38, 41, 39, 40, 41)	0.12 (± 0.34)	-0.08 (± 0.37)
Lymphocytes Week 4 (41, 39, 41, 39, 41, 40)	0.11 (± 0.36)	0.06 (± 0.36)
Lymphocytes Week 6 (40, 38, 38, 36, 40, 40)	0.05 (± 0.37)	-0.05 (± 0.40)
Lymphocytes Week 8 (39, 37, 37, 34, 40, 40)	0.15 (± 0.45)	0.06 (± 0.42)
Lymphocytes Week 12 (38, 38, 37, 34, 40, 38)	0.14 (± 0.38)	-0.04 (± 0.37)
Lymphocytes SFU (4, 4, 4, 2, 1, 3)	0.00 (± 999)	0.50 (± 0.44)
Monocytes Week 1 (42, 39, 41, 40, 43, 42)	0.02 (± 0.17)	-0.03 (± 0.14)
Monocytes Week 2 (41, 38, 41, 39, 40, 41)	-0.04 (± 0.17)	-0.03 (± 0.15)
Monocytes Week 4 (41, 39, 41, 39, 41, 40)	-0.01 (± 0.17)	0.02 (± 0.17)
Monocytes Week 6 (40, 38, 38, 36, 40, 40)	-0.02 (± 0.22)	-0.03 (± 0.18)
Monocytes Week 8 (39, 37, 37, 34, 40, 40)	-0.04 (± 0.17)	-0.02 (± 0.15)
Monocytes Week 12 (38, 38, 37, 34, 40, 38)	-0.07 (± 0.17)	-0.01 (± 0.14)
Monocytes SFU (4, 4, 4, 2, 1, 3)	-0.30 (± 999)	-0.07 (± 0.21)
Neutrophils Week 1 (42, 39, 41, 40, 43, 42)	-0.37 (± 1.20)	-0.44 (± 0.76)
Neutrophils Week 2 (41, 38, 41, 39, 40, 41)	-0.41 (± 1.64)	-0.36 (± 1.13)

Neutrophils Week 4 (41, 39, 41, 39, 41, 40)	-0.48 (± 1.60)	-0.40 (± 1.18)	
Neutrophils Week 6 (40, 38, 38, 36, 40, 40)	-0.50 (± 1.78)	-0.36 (± 1.01)	
Neutrophils Week 8 (39, 37, 37, 34, 40, 40)	-0.45 (± 1.61)	-0.47 (± 0.80)	
Neutrophils Week 12 (38, 38, 37, 34, 40, 38)	-0.59 (± 1.28)	-0.39 (± 0.93)	
Neutrophils SFU (4, 4, 4, 2, 1, 3)	0.50 (± 999)	-0.13 (± 0.38)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in biochemistry parameters (calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol, glucose)

End point title	Change from Baseline until Safety Follow-up Visit in biochemistry parameters (calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol, glucose)

End point description:

Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: mmol/L				
arithmetic mean (standard deviation)				
Calcium Week 1 (42, 39, 42, 40, 43, 43)	-0.010 (± 0.076)	0.011 (± 0.088)	-0.021 (± 0.126)	-0.017 (± 0.076)
Calcium Week 2 (42, 39, 41, 39, 42, 42)	-0.003 (± 0.082)	0.034 (± 0.094)	-0.007 (± 0.092)	0.004 (± 0.074)
Calcium Week 4 (41, 39, 41, 39, 41, 41)	-0.029 (± 0.073)	0.012 (± 0.099)	-0.020 (± 0.106)	-0.008 (± 0.074)
Calcium Week 6 (40, 38, 38, 37, 40, 40)	-0.033 (± 0.070)	0.009 (± 0.079)	-0.019 (± 0.091)	-0.008 (± 0.092)
Calcium Week 8 (39, 38, 38, 34, 40, 40)	-0.023 (± 0.084)	0.001 (± 0.106)	-0.027 (± 0.099)	0.019 (± 0.089)
Calcium Week 12 (39, 38, 38, 35, 40, 39)	-0.011 (± 0.095)	0.025 (± 0.092)	-0.038 (± 0.120)	0.001 (± 0.093)

Calcium SFU (4, 4, 4, 2, 1, 3)	-0.095 (± 0.083)	-0.050 (± 0.109)	-0.073 (± 0.045)	-0.125 (± 0.134)
Chloride Week 1 (42, 39, 42, 40, 43, 43)	0.5 (± 1.8)	0.6 (± 2.0)	0.6 (± 2.3)	0.6 (± 2.5)
Chloride Week 2 (42, 39, 41, 39, 42, 43)	0.0 (± 2.3)	0.1 (± 2.4)	-0.3 (± 2.2)	0.4 (± 2.3)
Chloride Week 4 (41, 39, 41, 39, 41, 41)	0.1 (± 1.8)	0.8 (± 2.1)	0.0 (± 2.5)	0.2 (± 2.3)
Chloride Week 6 (40, 38, 38, 37, 40, 40)	-0.1 (± 2.1)	0.0 (± 2.3)	-0.6 (± 1.7)	0.0 (± 2.4)
Chloride Week 8 (39, 38, 38, 34, 40, 40)	0.2 (± 2.1)	0.3 (± 2.3)	0.3 (± 2.0)	-0.1 (± 2.9)
Chloride Week 12 (39, 38, 38, 35, 40, 39)	0.3 (± 1.7)	-0.1 (± 2.5)	-0.2 (± 2.0)	0.2 (± 2.3)
Chloride SFU (4, 4, 4, 2, 1, 3)	1.0 (± 1.6)	3.0 (± 2.7)	0.5 (± 5.4)	2.0 (± 0.0)
Potassium Week 1 (42, 39, 42, 40, 43, 42)	0.08 (± 0.45)	0.08 (± 0.33)	0.05 (± 0.41)	0.02 (± 0.36)
Potassium Week 2 (42, 39, 41, 39, 42, 42)	0.03 (± 0.30)	0.08 (± 0.33)	0.02 (± 0.32)	-0.06 (± 0.29)
Potassium Week 4 (41, 39, 41, 39, 41, 40)	0.09 (± 0.40)	0.12 (± 0.41)	0.09 (± 0.38)	0.01 (± 0.34)
Potassium Week 6 (39, 38, 38, 37, 40, 40)	-0.04 (± 0.32)	0.11 (± 0.35)	-0.03 (± 0.31)	-0.07 (± 0.33)
Potassium Week 8 (39, 38, 38, 34, 40, 40)	0.01 (± 0.39)	0.07 (± 0.36)	0.12 (± 0.38)	-0.06 (± 0.38)
Potassium Week 12 (39, 37, 38, 35, 40, 39)	-0.05 (± 0.35)	0.08 (± 0.34)	0.08 (± 0.37)	-0.06 (± 0.37)
Potassium SFU (4, 4, 4, 2, 1, 3)	0.10 (± 0.36)	0.10 (± 0.37)	-0.10 (± 0.29)	-0.45 (± 0.07)
Magnesium Week 1 (42, 39, 42, 40, 43, 43)	-0.010 (± 0.074)	-0.002 (± 0.052)	-0.020 (± 0.069)	0.005 (± 0.079)
Magnesium Week 2 (41, 39, 41, 39, 42, 42)	-0.012 (± 0.063)	-0.004 (± 0.064)	-0.010 (± 0.065)	0.001 (± 0.068)
Magnesium Week 4 (41, 39, 41, 39, 41, 41)	-0.023 (± 0.077)	-0.004 (± 0.062)	-0.017 (± 0.046)	0.008 (± 0.071)
Magnesium Week 6 (40, 38, 38, 37, 40, 40)	-0.013 (± 0.054)	-0.014 (± 0.053)	-0.013 (± 0.057)	-0.008 (± 0.065)
Magnesium Week 8 (39, 38, 38, 34, 40, 40)	-0.026 (± 0.070)	-0.023 (± 0.042)	-0.023 (± 0.063)	0.003 (± 0.071)
Magnesium Week 12 (39, 38, 38, 35, 40, 39)	-0.014 (± 0.093)	0.007 (± 0.074)	-0.025 (± 0.069)	0.009 (± 0.074)
Magnesium SFU (4, 4, 4, 2, 1, 3)	0.053 (± 0.093)	0.110 (± 0.295)	-0.035 (± 0.047)	-0.050 (± 0.057)
Sodium Week 1 (42, 39, 42, 40, 43, 43)	-0.1 (± 1.8)	0.2 (± 1.7)	0.3 (± 2.7)	0.1 (± 1.9)
Sodium Week 2 (41, 39, 41, 39, 42, 42)	-0.3 (± 1.7)	-0.2 (± 1.4)	-0.4 (± 1.8)	0.0 (± 2.0)
Sodium Week 4 (41, 39, 41, 39, 41, 41)	-0.2 (± 1.7)	0.2 (± 1.7)	0.2 (± 1.7)	-0.2 (± 1.7)
Sodium Week 6 (40, 38, 38, 37, 40, 40)	-0.5 (± 2.0)	-0.1 (± 2.1)	-0.8 (± 1.6)	-0.1 (± 1.9)
Sodium Week 8 (39, 38, 38, 34, 40, 40)	-0.6 (± 2.0)	0.0 (± 2.8)	-0.2 (± 1.8)	-0.2 (± 2.0)
Sodium Week 12 (39, 38, 38, 35, 40, 39)	-0.4 (± 2.0)	-0.2 (± 1.7)	-0.1 (± 1.7)	-0.2 (± 2.0)
Sodium SFU (4, 4, 4, 2, 1, 3)	-0.5 (± 2.1)	0.8 (± 1.7)	-2.0 (± 2.2)	-2.0 (± 2.8)
Urea Nitrogen Week 1 (42, 39, 42, 40, 43, 43)	-0.16 (± 1.09)	0.11 (± 1.12)	0.27 (± 1.19)	0.34 (± 1.22)
Urea Nitrogen Week 2 (42, 39, 41, 39, 42, 42)	0.00 (± 1.16)	-0.03 (± 1.25)	0.24 (± 1.16)	0.16 (± 1.17)
Urea Nitrogen Week 4 (41, 39, 41, 39, 41, 41)	-0.14 (± 1.16)	0.48 (± 1.52)	0.50 (± 1.31)	-0.03 (± 1.20)
Urea Nitrogen Week 6 (40, 38, 38, 37, 40, 40)	-0.12 (± 0.96)	0.21 (± 1.40)	0.41 (± 1.14)	0.19 (± 1.31)
Urea Nitrogen Week 8 (39, 38, 38, 34, 40, 40)	-0.28 (± 1.29)	0.14 (± 1.33)	0.32 (± 1.08)	-0.08 (± 1.58)

End point values				
Urea Nitrogen Week 12 (39, 38, 38, 35, 40, 39)	-0.17 (± 1.35)	-0.04 (± 1.37)	0.39 (± 1.14)	0.08 (± 1.13)
Urea Nitrogen SFU (4, 4, 4, 2, 1, 3)	0.65 (± 1.74)	0.80 (± 1.19)	0.78 (± 3.27)	-0.65 (± 2.05)
Cholesterol Week 1 (42, 39, 42, 40, 43, 43)	-0.04 (± 0.47)	-0.06 (± 0.54)	0.00 (± 0.65)	-0.09 (± 0.59)
Cholesterol Week 2 (42, 39, 41, 39, 42, 42)	-0.13 (± 0.71)	0.03 (± 0.63)	0.12 (± 0.58)	-0.11 (± 0.52)
Cholesterol Week 4 (41, 39, 41, 39, 41, 41)	-0.06 (± 0.59)	0.04 (± 0.63)	0.17 (± 0.55)	-0.31 (± 0.88)
Cholesterol Week 6 (40, 38, 38, 37, 40, 40)	0.05 (± 0.46)	-0.02 (± 0.73)	0.17 (± 0.56)	-0.24 (± 0.70)
Cholesterol Week 8 (39, 38, 38, 34, 40, 40)	-0.08 (± 0.67)	-0.17 (± 0.68)	0.16 (± 0.64)	-0.13 (± 0.83)
Cholesterol Week 12 (39, 38, 38, 35, 40, 39)	-0.20 (± 0.88)	-0.07 (± 0.62)	0.11 (± 0.62)	-0.18 (± 0.77)
Cholesterol SFU (4, 4, 4, 2, 1, 3)	-0.28 (± 0.30)	-0.83 (± 1.56)	0.38 (± 0.52)	-0.80 (± 0.14)
Glucose Week 1 (42, 39, 42, 40, 43, 42)	0.50 (± 1.59)	0.12 (± 0.82)	-0.14 (± 1.00)	-0.06 (± 1.14)
Glucose Week 2 (41, 39, 41, 39, 42, 42)	0.29 (± 1.62)	0.17 (± 1.23)	-0.05 (± 0.92)	-0.20 (± 1.13)
Glucose Week 4 (41, 39, 41, 39, 41, 40)	0.37 (± 1.42)	0.25 (± 1.22)	-0.12 (± 1.03)	-0.09 (± 1.24)
Glucose Week 6 (39, 38, 38, 37, 40, 40)	0.44 (± 1.42)	0.30 (± 1.15)	-0.04 (± 1.26)	0.02 (± 1.60)
Glucose Week 8 (39, 38, 38, 34, 40, 40)	0.37 (± 1.48)	0.22 (± 1.48)	-0.15 (± 0.87)	-0.06 (± 1.43)
Glucose Week 12 (39, 37, 38, 35, 40, 39)	0.22 (± 1.27)	0.01 (± 1.08)	0.02 (± 1.35)	-0.17 (± 1.23)
Glucose SFU (4, 4, 4, 2, 1, 3)	-0.40 (± 0.48)	0.75 (± 0.89)	-0.33 (± 0.67)	-0.25 (± 0.49)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: mmol/L				
arithmetic mean (standard deviation)				
Calcium Week 1 (42, 39, 42, 40, 43, 43)	0.000 (± 0.077)	-0.010 (± 0.080)		
Calcium Week 2 (42, 39, 41, 39, 42, 42)	0.006 (± 0.088)	-0.006 (± 0.085)		
Calcium Week 4 (41, 39, 41, 39, 41, 41)	0.005 (± 0.099)	-0.010 (± 0.084)		
Calcium Week 6 (40, 38, 38, 37, 40, 40)	-0.026 (± 0.086)	-0.027 (± 0.100)		
Calcium Week 8 (39, 38, 38, 34, 40, 40)	-0.002 (± 0.089)	-0.016 (± 0.084)		
Calcium Week 12 (39, 38, 38, 35, 40, 39)	-0.019 (± 0.121)	-0.001 (± 0.092)		
Calcium SFU (4, 4, 4, 2, 1, 3)	0.020 (± 999)	0.020 (± 0.193)		
Chloride Week 1 (42, 39, 42, 40, 43, 43)	0.3 (± 2.1)	0.1 (± 1.8)		
Chloride Week 2 (42, 39, 41, 39, 42, 43)	0.5 (± 2.1)	0.1 (± 1.9)		
Chloride Week 4 (41, 39, 41, 39, 41, 41)	-0.1 (± 2.6)	-0.1 (± 1.9)		
Chloride Week 6 (40, 38, 38, 37, 40, 40)	-0.1 (± 3.0)	0.1 (± 2.0)		
Chloride Week 8 (39, 38, 38, 34, 40, 40)	0.1 (± 2.4)	0.1 (± 2.3)		

Chloride Week 12 (39, 38, 38, 35, 40, 39)	0.8 (± 2.4)	0.1 (± 2.2)		
Chloride SFU (4, 4, 4, 2, 1, 3)	0.0 (± 999)	0.3 (± 2.1)		
Potassium Week 1 (42, 39, 42, 40, 43, 42)	-0.03 (± 0.32)	0.04 (± 0.29)		
Potassium Week 2 (42, 39, 41, 39, 42, 42)	0.05 (± 0.37)	-0.03 (± 0.39)		
Potassium Week 4 (41, 39, 41, 39, 41, 40)	0.05 (± 0.40)	0.03 (± 0.33)		
Potassium Week 6 (39, 38, 38, 37, 40, 40)	-0.07 (± 0.34)	-0.02 (± 0.35)		
Potassium Week 8 (39, 38, 38, 34, 40, 40)	-0.12 (± 0.40)	0.02 (± 0.35)		
Potassium Week 12 (39, 37, 38, 35, 40, 39)	-0.07 (± 0.37)	-0.06 (± 0.33)		
Potassium SFU (4, 4, 4, 2, 1, 3)	0.20 (± 999)	-0.20 (± 0.30)		
Magnesium Week 1 (42, 39, 42, 40, 43, 43)	-0.007 (± 0.077)	-0.009 (± 0.064)		
Magnesium Week 2 (41, 39, 41, 39, 42, 42)	-0.017 (± 0.086)	0.005 (± 0.075)		
Magnesium Week 4 (41, 39, 41, 39, 41, 41)	-0.017 (± 0.067)	-0.013 (± 0.070)		
Magnesium Week 6 (40, 38, 38, 37, 40, 40)	-0.020 (± 0.073)	-0.017 (± 0.063)		
Magnesium Week 8 (39, 38, 38, 34, 40, 40)	-0.019 (± 0.072)	-0.021 (± 0.058)		
Magnesium Week 12 (39, 38, 38, 35, 40, 39)	-0.017 (± 0.075)	-0.008 (± 0.056)		
Magnesium SFU (4, 4, 4, 2, 1, 3)	-0.060 (± 999)	-0.023 (± 0.025)		
Sodium Week 1 (42, 39, 42, 40, 43, 43)	0.0 (± 2.2)	0.0 (± 1.4)		
Sodium Week 2 (41, 39, 41, 39, 42, 42)	0.2 (± 2.3)	0.0 (± 1.5)		
Sodium Week 4 (41, 39, 41, 39, 41, 41)	-0.1 (± 2.3)	-0.2 (± 1.7)		
Sodium Week 6 (40, 38, 38, 37, 40, 40)	-0.1 (± 2.9)	-0.3 (± 1.7)		
Sodium Week 8 (39, 38, 38, 34, 40, 40)	-0.1 (± 2.2)	-0.6 (± 2.0)		
Sodium Week 12 (39, 38, 38, 35, 40, 39)	-0.2 (± 2.4)	-0.3 (± 1.9)		
Sodium SFU (4, 4, 4, 2, 1, 3)	-1.0 (± 999)	-1.7 (± 1.2)		
Urea Nitrogen Week 1 (42, 39, 42, 40, 43, 43)	0.27 (± 1.24)	0.21 (± 0.88)		
Urea Nitrogen Week 2 (42, 39, 41, 39, 42, 42)	0.27 (± 1.17)	0.37 (± 1.03)		
Urea Nitrogen Week 4 (41, 39, 41, 39, 41, 41)	-0.11 (± 1.08)	0.15 (± 1.04)		
Urea Nitrogen Week 6 (40, 38, 38, 37, 40, 40)	0.29 (± 1.14)	0.12 (± 0.93)		
Urea Nitrogen Week 8 (39, 38, 38, 34, 40, 40)	0.33 (± 1.30)	0.35 (± 0.88)		
Urea Nitrogen Week 12 (39, 38, 38, 35, 40, 39)	0.13 (± 1.08)	0.01 (± 0.85)		
Urea Nitrogen SFU (4, 4, 4, 2, 1, 3)	-0.30 (± 999)	0.77 (± 1.27)		
Cholesterol Week 1 (42, 39, 42, 40, 43, 43)	0.12 (± 0.65)	0.06 (± 0.34)		
Cholesterol Week 2 (42, 39, 41, 39, 42, 42)	0.12 (± 1.04)	0.05 (± 0.57)		
Cholesterol Week 4 (41, 39, 41, 39, 41, 41)	0.00 (± 1.30)	0.05 (± 0.66)		
Cholesterol Week 6 (40, 38, 38, 37, 40, 40)	-0.24 (± 1.32)	0.08 (± 0.60)		

Cholesterol Week 8 (39, 38, 38, 34, 40, 40)	-0.17 (± 1.22)	0.01 (± 0.48)		
Cholesterol Week 12 (39, 38, 38, 35, 40, 39)	0.01 (± 1.29)	-0.05 (± 0.76)		
Cholesterol SFU (4, 4, 4, 2, 1, 3)	0.20 (± 999)	0.40 (± 0.44)		
Glucose Week 1 (42, 39, 42, 40, 43, 42)	0.07 (± 1.10)	0.22 (± 0.70)		
Glucose Week 2 (41, 39, 41, 39, 42, 42)	0.03 (± 1.09)	0.05 (± 0.67)		
Glucose Week 4 (41, 39, 41, 39, 41, 40)	0.37 (± 1.20)	0.19 (± 0.92)		
Glucose Week 6 (39, 38, 38, 37, 40, 40)	0.21 (± 1.30)	0.29 (± 1.27)		
Glucose Week 8 (39, 38, 38, 34, 40, 40)	0.11 (± 1.10)	0.03 (± 0.97)		
Glucose Week 12 (39, 37, 38, 35, 40, 39)	-0.15 (± 0.88)	0.04 (± 0.95)		
Glucose SFU (4, 4, 4, 2, 1, 3)	0.20 (± 999)	-0.17 (± 0.61)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in biochemistry parameters (lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase)

End point title	Change from Baseline until Safety Follow-up Visit in biochemistry parameters (lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase)

End point description:

Lactate dehydrogenase (LDH), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT) were measured in units per liter (U/L). The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: U/L				
arithmetic mean (standard deviation)				
LDH Week 1 (42, 39, 42, 40, 43, 43)	-2.0 (± 29.4)	1.1 (± 24.8)	-5.0 (± 24.1)	-0.3 (± 21.4)
LDH Week 2 (42, 39, 41, 39, 42, 42)	-4.9 (± 26.4)	-2.5 (± 25.2)	-3.5 (± 22.1)	0.4 (± 27.6)
LDH Week 4 (41, 39, 41, 39, 41, 41)	-4.9 (± 22.4)	1.7 (± 31.9)	-8.1 (± 16.7)	5.0 (± 43.5)
LDH Week 6 (40, 38, 38, 37, 40, 40)	-5.0 (± 27.7)	-1.4 (± 25.2)	-7.3 (± 20.3)	2.0 (± 16.2)
LDH Week 8 (39, 38, 38, 34, 40, 40)	-5.5 (± 27.4)	0.5 (± 25.2)	-12.3 (± 22.2)	-0.8 (± 18.9)

LDH Week 12 (39, 38, 38, 35, 40, 39)	-4.9 (± 28.1)	2.9 (± 26.7)	-7.5 (± 25.1)	-0.3 (± 20.6)
LDH SFU (4, 4, 4, 2, 1, 3)	-1.5 (± 12.9)	-5.0 (± 18.4)	3.3 (± 81.2)	-45.5 (± 16.3)
ALP Week 1 (42, 39, 42, 40, 43, 43)	-1.8 (± 6.3)	-0.5 (± 6.0)	-3.5 (± 8.2)	-3.8 (± 7.7)
ALP Week 2 (42, 39, 41, 39, 42, 42)	-3.0 (± 12.7)	0.0 (± 7.4)	-2.5 (± 10.5)	-2.7 (± 8.2)
ALP Week 4 (41, 39, 41, 39, 41, 41)	-2.4 (± 8.7)	-1.9 (± 9.2)	-6.2 (± 9.8)	-4.3 (± 9.4)
ALP Week 6 (40, 38, 38, 37, 40, 40)	-3.0 (± 8.3)	-1.8 (± 9.0)	-5.5 (± 10.0)	-2.4 (± 8.6)
ALP Week 8 (39, 38, 38, 34, 40, 40)	-4.3 (± 12.2)	-1.7 (± 8.0)	-4.2 (± 11.2)	-2.1 (± 10.0)
ALP Week 12 (39, 38, 38, 35, 40, 39)	-2.0 (± 8.1)	0.3 (± 7.2)	-2.4 (± 11.8)	-0.4 (± 9.0)
ALP SFU (4, 4, 4, 2, 1, 3)	-0.5 (± 7.4)	9.8 (± 8.9)	7.8 (± 15.3)	-3.0 (± 5.7)
ALT Week 1 (42, 39, 42, 40, 43, 43)	2.0 (± 7.7)	2.1 (± 10.4)	-1.7 (± 13.7)	1.6 (± 12.2)
ALT Week 2 (42, 39, 41, 39, 42, 42)	0.3 (± 6.5)	1.9 (± 9.0)	2.0 (± 29.8)	-0.9 (± 7.7)
ALT Week 1 (41, 39, 41, 39, 41, 41)	-0.2 (± 7.0)	1.1 (± 8.6)	0.8 (± 18.7)	-0.4 (± 10.2)
ALT Week 6 (40, 38, 38, 37, 40, 40)	3.9 (± 18.9)	1.1 (± 8.9)	-0.6 (± 11.7)	3.5 (± 20.9)
ALT Week 8 (39, 38, 38, 34, 40, 40)	1.8 (± 10.8)	2.2 (± 10.2)	0.1 (± 10.5)	-0.4 (± 9.7)
ALT Week 12 (39, 38, 38, 35, 40, 39)	-1.3 (± 7.5)	1.8 (± 9.9)	-1.0 (± 10.8)	-0.9 (± 9.1)
ALT SFU (4, 4, 4, 2, 1, 3)	-3.8 (± 3.0)	4.3 (± 3.4)	26.5 (± 42.1)	-6.0 (± 8.5)
AST Week 1 (42, 39, 42, 40, 43, 43)	0.5 (± 6.1)	2.0 (± 10.8)	-3.0 (± 15.2)	1.9 (± 11.5)
AST Week 2 (42, 39, 41, 39, 42, 42)	-1.0 (± 3.8)	0.4 (± 4.9)	-1.9 (± 19.1)	-0.9 (± 4.7)
AST Week 4 (41, 39, 41, 39, 41, 41)	-1.1 (± 4.8)	-0.1 (± 5.8)	-2.5 (± 17.5)	-0.4 (± 5.9)
AST Week 6 (40, 38, 38, 37, 40, 40)	1.5 (± 10.6)	0.8 (± 6.0)	-0.9 (± 9.5)	4.0 (± 15.7)
AST Week 8 (39, 38, 38, 34, 40, 40)	0.0 (± 5.1)	0.2 (± 6.7)	-1.4 (± 5.4)	-1.4 (± 4.6)
AST Week 12 (39, 38, 38, 35, 40, 39)	-1.3 (± 5.5)	1.1 (± 7.9)	-1.4 (± 8.3)	-0.3 (± 4.8)
AST SFU (4, 4, 4, 2, 1, 3)	-2.8 (± 1.7)	-0.3 (± 2.1)	11.5 (± 23.5)	-4.0 (± 2.8)
GGT Week 1 (42, 39, 42, 40, 43, 43)	0.6 (± 6.4)	-0.8 (± 14.1)	-2.0 (± 10.7)	-7.5 (± 42.1)
GGT Week 2 (42, 39, 41, 39, 42, 42)	0.2 (± 8.7)	-1.6 (± 11.1)	0.2 (± 14.2)	-1.2 (± 8.0)
GGT Week 4 (41, 39, 41, 39, 41, 41)	-0.7 (± 8.5)	-1.9 (± 11.8)	1.8 (± 18.6)	-2.6 (± 12.8)
GGT Week 6 (40, 38, 38, 37, 40, 40)	1.8 (± 10.5)	-1.8 (± 13.8)	-2.9 (± 13.1)	-2.9 (± 7.3)
GGT Week 8 (39, 38, 38, 34, 40, 40)	2.4 (± 13.7)	-1.9 (± 14.9)	-0.9 (± 18.4)	-2.6 (± 13.6)
GGT Week 12 (39, 38, 38, 35, 40, 39)	-0.4 (± 10.9)	-2.2 (± 13.3)	-1.1 (± 21.7)	-0.6 (± 11.2)
GGT SFU (4, 4, 4, 2, 1, 3)	-8.0 (± 13.4)	1.3 (± 3.9)	19.8 (± 23.3)	-16.5 (± 24.7)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: U/L				
arithmetic mean (standard deviation)				
LDH Week 1 (42, 39, 42, 40, 43, 43)	-4.6 (± 18.9)	-3.4 (± 19.7)		
LDH Week 2 (42, 39, 41, 39, 42, 42)	-7.6 (± 27.4)	-5.1 (± 20.1)		
LDH Week 4 (41, 39, 41, 39, 41, 41)	-4.5 (± 37.7)	-4.4 (± 15.4)		
LDH Week 6 (40, 38, 38, 37, 40, 40)	-11.0 (± 27.5)	-3.5 (± 22.6)		
LDH Week 8 (39, 38, 38, 34, 40, 40)	-10.7 (± 33.1)	-3.7 (± 27.5)		
LDH Week 12 (39, 38, 38, 35, 40, 39)	-5.6 (± 33.1)	-4.4 (± 24.8)		
LDH SFU (4, 4, 4, 2, 1, 3)	15.0 (± 999)	32.3 (± 34.2)		
ALP Week 1 (42, 39, 42, 40, 43, 43)	-1.9 (± 5.3)	-2.3 (± 5.7)		
ALP Week 2 (42, 39, 41, 39, 42, 42)	-1.6 (± 6.5)	-1.7 (± 7.7)		
ALP Week 4 (41, 39, 41, 39, 41, 41)	-2.6 (± 8.1)	-1.7 (± 7.8)		
ALP Week 6 (40, 38, 38, 37, 40, 40)	-2.1 (± 9.6)	-1.4 (± 7.5)		
ALP Week 8 (39, 38, 38, 34, 40, 40)	-1.1 (± 11.3)	-1.9 (± 7.2)		

ALP Week 12 (39, 38, 38, 35, 40, 39)	-0.5 (± 10.4)	-0.4 (± 8.4)		
ALP SFU (4, 4, 4, 2, 1, 3)	3.0 (± 999)	3.0 (± 1.0)		
ALT Week 1 (42, 39, 42, 40, 43, 43)	0.7 (± 8.9)	1.2 (± 9.1)		
ALT Week 2 (42, 39, 41, 39, 42, 42)	-0.2 (± 10.2)	1.6 (± 11.5)		
ALT Week 1 (41, 39, 41, 39, 41, 41)	0.4 (± 14.7)	1.0 (± 13.3)		
ALT Week 6 (40, 38, 38, 37, 40, 40)	-1.7 (± 13.7)	1.1 (± 12.5)		
ALT Week 8 (39, 38, 38, 34, 40, 40)	-1.1 (± 14.5)	0.8 (± 9.0)		
ALT Week 12 (39, 38, 38, 35, 40, 39)	-0.9 (± 14.6)	-0.4 (± 10.6)		
ALT SFU (4, 4, 4, 2, 1, 3)	16.0 (± 999)	-3.3 (± 3.1)		
AST Week 1 (42, 39, 42, 40, 43, 43)	0.3 (± 6.3)	-0.5 (± 7.2)		
AST Week 2 (42, 39, 41, 39, 42, 42)	-0.5 (± 6.1)	0.9 (± 13.4)		
AST Week 4 (41, 39, 41, 39, 41, 41)	0.6 (± 8.2)	-0.4 (± 7.5)		
AST Week 6 (40, 38, 38, 37, 40, 40)	-1.4 (± 7.0)	-1.4 (± 6.5)		
AST Week 8 (39, 38, 38, 34, 40, 40)	-0.4 (± 8.3)	-0.8 (± 6.3)		
AST Week 12 (39, 38, 38, 35, 40, 39)	-0.5 (± 7.3)	-0.9 (± 5.2)		
AST SFU (4, 4, 4, 2, 1, 3)	9.0 (± 999)	0.7 (± 2.5)		
GGT Week 1 (42, 39, 42, 40, 43, 43)	1.6 (± 22.9)	-0.8 (± 6.3)		
GGT Week 2 (42, 39, 41, 39, 42, 42)	-1.9 (± 6.5)	0.4 (± 15.0)		
GGT Week 4 (41, 39, 41, 39, 41, 41)	-0.4 (± 8.4)	-1.4 (± 14.1)		
GGT Week 6 (40, 38, 38, 37, 40, 40)	-2.1 (± 9.3)	-1.1 (± 12.9)		
GGT Week 8 (39, 38, 38, 34, 40, 40)	-2.5 (± 9.4)	3.1 (± 29.5)		
GGT Week 12 (39, 38, 38, 35, 40, 39)	-0.4 (± 11.1)	-0.9 (± 12.2)		
GGT SFU (4, 4, 4, 2, 1, 3)	37.0 (± 999)	3.0 (± 3.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in biochemistry parameters (creatinine, bilirubin)

End point title	Change from Baseline until Safety Follow-up Visit in biochemistry parameters (creatinine, bilirubin)

End point description:

Creatinine and bilirubin were measured in micromols per liter (µmol/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: µmol/L				
arithmetic mean (standard deviation)				
Creatinine Week 1 (42, 39, 42, 40, 43, 43)	0.6 (± 7.0)	2.7 (± 10.1)	1.4 (± 8.6)	0.6 (± 8.1)
Creatinine Week 2 (42, 39, 41, 39, 42, 42)	0.0 (± 7.1)	-0.8 (± 8.2)	-0.4 (± 10.1)	-0.7 (± 8.5)
Creatinine Week 4 (41, 39, 41, 39, 41, 41)	0.0 (± 5.8)	1.3 (± 9.1)	0.6 (± 7.9)	-1.7 (± 8.1)
Creatinine Week 6 (40, 38, 38, 37, 40, 40)	-1.1 (± 7.8)	1.6 (± 10.5)	-0.1 (± 10.6)	-0.6 (± 7.9)
Creatinine Week 8 (39, 38, 38, 34, 40, 40)	-1.1 (± 6.2)	-0.4 (± 7.4)	-1.0 (± 9.6)	-2.6 (± 8.4)
Creatinine Week 12 (39, 38, 38, 35, 40, 39)	-1.6 (± 7.8)	-0.2 (± 7.0)	0.7 (± 12.0)	-0.7 (± 9.1)
Creatinine SFU (4, 4, 4, 2, 1, 3)	1.5 (± 4.4)	6.0 (± 4.3)	-6.5 (± 4.4)	-10.5 (± 16.3)
Bilirubin Week 1 (42, 39, 42, 40, 43, 43)	-0.53 (± 3.10)	-1.79 (± 4.50)	-0.52 (± 2.81)	-0.55 (± 4.49)
Bilirubin Week 2 (42, 39, 41, 39, 42, 42)	-0.35 (± 2.85)	-0.86 (± 5.05)	-0.48 (± 3.40)	-0.38 (± 3.60)
Bilirubin Week 4 (41, 39, 41, 39, 41, 41)	-0.70 (± 3.26)	-1.70 (± 4.92)	-0.26 (± 3.53)	-0.04 (± 2.74)
Bilirubin Week 6 (40, 38, 38, 37, 40, 40)	-0.51 (± 3.13)	-1.15 (± 4.59)	0.35 (± 3.44)	-0.33 (± 3.94)
Bilirubin Week 8 (39, 38, 38, 34, 40, 40)	-0.21 (± 3.81)	-0.98 (± 4.68)	-0.30 (± 3.20)	-0.43 (± 4.52)
Bilirubin Week 12 (39, 38, 38, 35, 40, 39)	-0.74 (± 3.43)	-1.02 (± 5.24)	-0.73 (± 2.98)	-1.20 (± 3.37)
Bilirubin SFU (4, 4, 4, 2, 1, 3)	2.05 (± 2.16)	-1.23 (± 2.62)	-0.30 (± 3.87)	-0.25 (± 0.78)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: µmol/L				
arithmetic mean (standard deviation)				
Creatinine Week 1 (42, 39, 42, 40, 43, 43)	0.7 (± 8.4)	-0.7 (± 7.7)		
Creatinine Week 2 (42, 39, 41, 39, 42, 42)	-0.1 (± 8.3)	0.0 (± 7.1)		
Creatinine Week 4 (41, 39, 41, 39, 41, 41)	0.6 (± 8.1)	1.6 (± 7.2)		
Creatinine Week 6 (40, 38, 38, 37, 40, 40)	-0.1 (± 8.1)	-0.5 (± 11.1)		
Creatinine Week 8 (39, 38, 38, 34, 40, 40)	-0.1 (± 7.6)	0.1 (± 8.3)		
Creatinine Week 12 (39, 38, 38, 35, 40, 39)	0.1 (± 9.0)	-0.7 (± 7.2)		
Creatinine SFU (4, 4, 4, 2, 1, 3)	9.0 (± 999)	1.3 (± 6.4)		
Bilirubin Week 1 (42, 39, 42, 40, 43, 43)	0.57 (± 5.73)	0.14 (± 4.16)		

Bilirubin Week 2 (42, 39, 41, 39, 42, 42)	-0.99 (± 2.98)	0.27 (± 3.69)	
Bilirubin Week 4 (41, 39, 41, 39, 41, 41)	0.76 (± 4.27)	0.70 (± 4.52)	
Bilirubin Week 6 (40, 38, 38, 37, 40, 40)	0.11 (± 4.19)	-0.30 (± 4.28)	
Bilirubin Week 8 (39, 38, 38, 34, 40, 40)	-0.15 (± 3.79)	-0.02 (± 4.41)	
Bilirubin Week 12 (39, 38, 38, 35, 40, 39)	-0.43 (± 3.68)	-0.34 (± 3.45)	
Bilirubin SFU (4, 4, 4, 2, 1, 3)	-1.50 (± 999)	1.40 (± 2.96)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in biochemistry parameters (C Reactive Protein)

End point title	Change from Baseline until Safety Follow-up Visit in biochemistry parameters (C Reactive Protein)

End point description:

C Reactive Protein was measured in milligrams per liters (mg/L).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed and for groups that had 0 participants analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: mg/L				
arithmetic mean (standard deviation)				
Week 1 (15, 10, 6, 8, 12, 10)	-2.110 (± 5.255)	-5.367 (± 11.806)	-0.775 (± 2.020)	-2.635 (± 2.550)
Week 2 (11, 10, 7, 9, 9, 9)	1.821 (± 6.974)	-6.985 (± 11.064)	0.576 (± 2.898)	2.743 (± 15.212)
Week 4 (11, 10, 6, 7, 10, 8)	1.338 (± 11.182)	-5.835 (± 8.594)	-1.722 (± 5.596)	0.929 (± 8.047)
Week 6 (14, 8, 7, 4, 8, 6)	2.978 (± 13.162)	-5.930 (± 9.560)	-4.516 (± 11.304)	-0.595 (± 7.346)
Week 8 (12, 8, 7, 4, 9, 5)	3.153 (± 18.764)	-6.891 (± 15.192)	-3.143 (± 10.844)	2.590 (± 7.755)
Week 12 (10, 11, 6, 4, 8, 8)	7.279 (± 13.546)	-5.193 (± 10.817)	0.695 (± 6.381)	-3.033 (± 7.261)

SFU (1, 0, 0, 0, 0, 0)	8.000 (± 999)	999 (± 999)	999 (± 999)	999 (± 999)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: mg/L				
arithmetic mean (standard deviation)				
Week 1 (15, 10, 6, 8, 12, 10)	-5.108 (± 10.013)	-3.732 (± 3.997)		
Week 2 (11, 10, 7, 9, 9, 9)	-6.763 (± 13.211)	-3.042 (± 1.989)		
Week 4 (11, 10, 6, 7, 10, 8)	-4.226 (± 9.865)	7.141 (± 32.344)		
Week 6 (14, 8, 7, 4, 8, 6)	1.799 (± 14.635)	-6.598 (± 6.278)		
Week 8 (12, 8, 7, 4, 9, 5)	12.434 (± 47.447)	-1.104 (± 5.201)		
Week 12 (10, 11, 6, 4, 8, 8)	-9.890 (± 10.729)	-5.368 (± 5.322)		
SFU (1, 0, 0, 0, 0, 0)	999 (± 999)	999 (± 999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in urinalysis parameters (pH)

End point title	Change from Baseline until Safety Follow-up Visit in urinalysis parameters (pH)

End point description:

Urine pH was measured on a pH scale.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	41	40
Units: ph				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 41, 40, 43, 43)	0.00 (± 0.79)	-0.10 (± 0.79)	-0.13 (± 0.88)	-0.20 (± 0.88)
Week 2 (42, 39, 39, 39, 42, 42)	0.06 (± 0.86)	-0.06 (± 0.86)	-0.10 (± 0.77)	-0.23 (± 0.92)
Week 4 (41, 39, 41, 39, 41, 40)	0.05 (± 0.87)	-0.09 (± 0.76)	-0.11 (± 0.95)	-0.26 (± 0.89)
Week 6 (40, 38, 38, 37, 40, 40)	-0.01 (± 0.73)	-0.03 (± 0.68)	-0.17 (± 0.69)	-0.18 (± 0.86)
Week 8 (39, 38, 38, 35, 40, 40)	-0.03 (± 0.92)	-0.07 (± 0.83)	-0.12 (± 1.07)	-0.34 (± 0.79)
Week 12 (39, 38, 37, 34, 40, 39)	-0.14 (± 0.79)	-0.01 (± 0.85)	0.01 (± 0.70)	-0.28 (± 0.85)
SFU (4, 4, 4, 2, 1, 3)	0.25 (± 1.04)	-0.25 (± 0.87)	0.50 (± 1.22)	-1.00 (± 1.41)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: ph				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 41, 40, 43, 43)	-0.08 (± 0.82)	-0.07 (± 0.90)		
Week 2 (42, 39, 39, 39, 42, 42)	-0.18 (± 0.76)	0.06 (± 0.65)		
Week 4 (41, 39, 41, 39, 41, 40)	-0.07 (± 0.73)	-0.04 (± 0.74)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.13 (± 0.81)	0.05 (± 0.86)		
Week 8 (39, 38, 38, 35, 40, 40)	-0.30 (± 0.91)	0.08 (± 0.75)		
Week 12 (39, 38, 37, 34, 40, 39)	-0.21 (± 0.99)	-0.01 (± 0.85)		
SFU (4, 4, 4, 2, 1, 3)	0.50 (± 999)	-0.17 (± 0.29)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (leukocyte esterase)

End point title	Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (leukocyte esterase)
End point description:	

Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.

End point type	Secondary
End point timeframe:	

From Baseline (Week 0) until Week 12

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	38	37	34
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0	0	0
Baseline Low – Week 12 Normal	0	0	0	0
Baseline Low – Week 12 High	0	0	0	0
Baseline Normal – Week 12 Low	0	0	0	0
Baseline Normal – Week 12 Normal	84.6	84.2	97.3	88.2
Baseline Normal – Week 12 High	2.6	0	2.7	5.9
Baseline High – Week 12 Low	0	0	0	0
Baseline High – Week 12 Normal	7.7	15.8	0	2.9
Baseline High – Week 12 High	5.1	0	0	2.9

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	39		
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0		
Baseline Low – Week 12 Normal	0	0		
Baseline Low – Week 12 High	0	0		
Baseline Normal – Week 12 Low	0	0		
Baseline Normal – Week 12 Normal	90.0	92.3		
Baseline Normal – Week 12 High	5.0	0		
Baseline High – Week 12 Low	0	0		
Baseline High – Week 12 Normal	5.0	7.7		
Baseline High – Week 12 High	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (nitrite)

End point title	Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (nitrite)

End point description:

Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.

The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.

End point type	Secondary

End point timeframe:
From Baseline (Week 0) until Week 12

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	38	37	34
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0	0	0
Baseline Low – Week 12 Normal	0	0	0	0
Baseline Low – Week 12 High	0	0	0	0
Baseline Normal – Week 12 Low	0	0	0	0
Baseline Normal – Week 12 Normal	97.4	97.4	100	100
Baseline Normal – Week 12 High	0	2.6	0	0
Baseline High – Week 12 Low	0	0	0	0
Baseline High – Week 12 Normal	0	0	0	0
Baseline High – Week 12 High	2.6	0	0	0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	39		
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0		
Baseline Low – Week 12 Normal	0	0		
Baseline Low – Week 12 High	0	0		
Baseline Normal – Week 12 Low	0	0		
Baseline Normal – Week 12 Normal	95.0	94.9		
Baseline Normal – Week 12 High	2.5	2.6		
Baseline High – Week 12 Low	0	0		
Baseline High – Week 12 Normal	0	2.6		
Baseline High – Week 12 High	2.5	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who shifted from Baseline until Week 12 in

urinalysis parameters (occult blood)

End point title	Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (occult blood)

End point description:

Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Week 12

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	38	37	34
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0	0	0
Baseline Low – Week 12 Normal	0	0	0	0
Baseline Low – Week 12 High	0	0	0	0
Baseline Normal – Week 12 Low	0	0	0	0
Baseline Normal – Week 12 Normal	76.9	86.8	83.8	79.4
Baseline Normal – Week 12 High	0	5.3	0	5.9
Baseline High – Week 12 Low	0	0	0	0
Baseline High – Week 12 Normal	10.3	5.3	5.4	8.8
Baseline High – Week 12 High	12.8	2.6	10.8	5.9

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	39		
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0		
Baseline Low – Week 12 Normal	0	0		
Baseline Low – Week 12 High	0	0		
Baseline Normal – Week 12 Low	0	0		
Baseline Normal – Week 12 Normal	77.5	89.7		
Baseline Normal – Week 12 High	5.0	2.6		
Baseline High – Week 12 Low	0	0		
Baseline High – Week 12 Normal	15.0	5.1		
Baseline High – Week 12 High	2.5	2.6		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (urine glucose)

End point title	Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (urine glucose)

End point description:

Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Week 12

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	38	37	34
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0	0	0
Baseline Low – Week 12 Normal	0	0	0	0
Baseline Low – Week 12 High	0	0	0	0
Baseline Normal – Week 12 Low	0	0	0	0
Baseline Normal – Week 12 Normal	94.9	94.7	97.3	97.1
Baseline Normal – Week 12 High	0	2.6	2.7	2.9
Baseline High – Week 12 Low	0	0	0	0
Baseline High – Week 12 Normal	0	0	0	0
Baseline High – Week 12 High	5.1	2.6	0	0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	39		
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0		
Baseline Low – Week 12 Normal	0	0		
Baseline Low – Week 12 High	0	0		
Baseline Normal – Week 12 Low	0	0		
Baseline Normal – Week 12 Normal	95.0	94.9		
Baseline Normal – Week 12 High	0	0		
Baseline High – Week 12 Low	0	0		
Baseline High – Week 12 Normal	2.5	0		

Baseline High – Week 12 High	2.5	5.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (albumin)

End point title	Percentage of participants who shifted from Baseline until Week 12 in urinalysis parameters (albumin)

End point description:

Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.
Number of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.

End point type	Secondary

End point timeframe:

From Baseline (Week 0) until Week 12

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	39	38	37	34
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0	0	0
Baseline Low – Week 12 Normal	0	0	0	0
Baseline Low – Week 12 High	0	0	0	0
Baseline Normal – Week 12 Low	0	0	0	0
Baseline Normal – Week 12 Normal	94.9	89.5	86.5	91.2
Baseline Normal – Week 12 High	0	7.9	2.7	2.9
Baseline High – Week 12 Low	0	0	0	0
Baseline High – Week 12 Normal	5.1	2.6	10.8	5.9
Baseline High – Week 12 High	0	0	0	0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	40	39		
Units: percentage of participants				
number (not applicable)				
Baseline Low – Week 12 Low	0	0		

Baseline Low – Week 12 Normal	0	0
Baseline Low – Week 12 High	0	0
Baseline Normal – Week 12 Low	0	0
Baseline Normal – Week 12 Normal	95.0	92.3
Baseline Normal – Week 12 High	2.5	0
Baseline High – Week 12 Low	0	0
Baseline High – Week 12 Normal	2.5	2.6
Baseline High – Week 12 High	0	5.1

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in vital signs (blood pressure)

End point title	Change from Baseline until Safety Follow-up Visit in vital signs (blood pressure)

End point description:

Blood pressure (BP) was measured in millimeters of mercury (mmHg).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: mmHg				
arithmetic mean (standard deviation)				
Systolic BP Week 1 (42, 39, 42, 40, 43, 43)	1.2 (± 10.7)	2.2 (± 7.1)	-3.9 (± 8.3)	1.7 (± 9.3)
Systolic BP Week 2 (42, 39, 41, 39, 42, 42)	-1.1 (± 9.7)	2.1 (± 9.4)	-2.7 (± 12.5)	0.2 (± 13.6)
Systolic BP Week 4 (42, 39, 41, 39, 41, 41)	-2.3 (± 10.0)	2.1 (± 7.9)	-1.9 (± 11.3)	0.1 (± 12.4)
Systolic BP Week 6 (40, 38, 38, 37, 40, 40)	-1.4 (± 9.8)	-1.3 (± 10.7)	-4.3 (± 10.6)	0.1 (± 12.8)
Systolic BP Week 8 (39, 38, 38, 37, 40, 40)	-0.8 (± 12.1)	-1.3 (± 13.0)	-3.4 (± 8.0)	0.1 (± 12.3)
Systolic BP Week 12 (39, 38, 38, 35, 40, 39)	-1.3 (± 10.9)	2.2 (± 9.0)	-2.9 (± 10.3)	-0.3 (± 11.8)
Systolic BP SFU (4, 4, 4, 2, 1, 3)	-7.0 (± 12.7)	-10.5 (± 17.0)	-1.3 (± 10.4)	4.5 (± 7.8)

Diastolic BP Week 1 (42, 39, 42, 40, 43, 43)	-0.4 (± 7.4)	0.9 (± 10.0)	-2.1 (± 7.3)	0.6 (± 6.5)
Diastolic BP Week 2 (42, 39, 41, 39, 42, 42)	-1.5 (± 6.9)	0.4 (± 8.7)	-1.2 (± 7.1)	2.1 (± 8.3)
Diastolic BP Week 4 (42, 39, 41, 39, 41, 41)	-0.3 (± 7.8)	0.6 (± 9.2)	-0.3 (± 7.9)	0.6 (± 7.3)
Diastolic BP Week 6 (40, 38, 38, 37, 40, 40)	0.3 (± 7.6)	0.0 (± 9.7)	-3.1 (± 7.9)	1.3 (± 8.6)
Diastolic BP Week 8 (39, 38, 38, 37, 40, 40)	-1.1 (± 8.9)	-0.3 (± 9.1)	-1.2 (± 7.3)	2.8 (± 8.7)
Diastolic BP Week 12 (39, 38, 38, 35, 40, 39)	-2.3 (± 5.8)	0.5 (± 6.3)	-1.7 (± 6.4)	3.1 (± 8.4)
Diastolic BP SFU (4, 4, 4, 2, 1, 3)	1.3 (± 8.5)	-9.0 (± 9.1)	0.8 (± 8.8)	-4.5 (± 0.7)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: mmHg				
arithmetic mean (standard deviation)				
Systolic BP Week 1 (42, 39, 42, 40, 43, 43)	0.2 (± 12.1)	-1.0 (± 9.9)		
Systolic BP Week 2 (42, 39, 41, 39, 42, 42)	-0.6 (± 8.4)	-3.2 (± 11.2)		
Systolic BP Week 4 (42, 39, 41, 39, 41, 41)	-0.1 (± 11.3)	-0.5 (± 10.8)		
Systolic BP Week 6 (40, 38, 38, 37, 40, 40)	-0.9 (± 10.9)	-2.4 (± 9.2)		
Systolic BP Week 8 (39, 38, 38, 37, 40, 40)	0.5 (± 12.5)	-1.0 (± 10.7)		
Systolic BP Week 12 (39, 38, 38, 35, 40, 39)	-1.2 (± 10.4)	-2.4 (± 10.1)		
Systolic BP SFU (4, 4, 4, 2, 1, 3)	-2.0 (± 999)	-2.0 (± 2.6)		
Diastolic BP Week 1 (42, 39, 42, 40, 43, 43)	0.3 (± 7.4)	0.1 (± 6.7)		
Diastolic BP Week 2 (42, 39, 41, 39, 42, 42)	0.0 (± 7.2)	0.2 (± 7.0)		
Diastolic BP Week 4 (42, 39, 41, 39, 41, 41)	0.0 (± 7.7)	0.3 (± 8.1)		
Diastolic BP Week 6 (40, 38, 38, 37, 40, 40)	0.1 (± 7.3)	-1.6 (± 7.3)		
Diastolic BP Week 8 (39, 38, 38, 37, 40, 40)	-0.7 (± 7.7)	-0.6 (± 8.2)		
Diastolic BP Week 12 (39, 38, 38, 35, 40, 39)	-1.1 (± 6.7)	-1.1 (± 7.3)		
Diastolic BP SFU (4, 4, 4, 2, 1, 3)	-9.0 (± 999)	-4.0 (± 6.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in vital signs (pulse

rate)

End point title	Change from Baseline until Safety Follow-up Visit in vital signs (pulse rate)

End point description:

Pulse rate was measured in beats per minute (beats/min).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: beats/min				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 43)	1.7 (± 9.5)	-1.6 (± 9.1)	3.2 (± 8.0)	-1.8 (± 8.1)
Week 2 (42, 39, 41, 39, 42, 42)	1.2 (± 8.4)	-1.3 (± 9.9)	1.1 (± 7.8)	-1.0 (± 10.4)
Week 4 (42, 39, 41, 39, 41, 41)	1.0 (± 10.2)	-3.1 (± 9.9)	0.6 (± 7.8)	-3.6 (± 9.0)
Week 6 (40, 38, 38, 37, 40, 40)	0.9 (± 9.8)	1.2 (± 10.7)	1.4 (± 8.3)	-2.6 (± 9.7)
Week 8 (39, 38, 38, 37, 40, 40)	1.7 (± 8.9)	-3.2 (± 9.3)	0.4 (± 9.2)	-1.8 (± 8.5)
Week 12 (39, 38, 38, 35, 40, 39)	0.9 (± 8.4)	-1.9 (± 6.8)	1.8 (± 11.0)	-3.1 (± 8.5)
SFU (4, 4, 4, 2, 1, 3)	-2.8 (± 2.6)	-2.5 (± 12.0)	2.3 (± 6.0)	1.5 (± 4.9)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: beats/min				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 43)	0.1 (± 6.4)	-0.4 (± 7.7)		
Week 2 (42, 39, 41, 39, 42, 42)	-2.2 (± 7.9)	0.5 (± 9.5)		
Week 4 (42, 39, 41, 39, 41, 41)	-1.6 (± 6.5)	1.6 (± 8.0)		
Week 6 (40, 38, 38, 37, 40, 40)	-1.7 (± 9.3)	2.6 (± 8.0)		
Week 8 (39, 38, 38, 37, 40, 40)	0.5 (± 8.2)	0.6 (± 6.7)		
Week 12 (39, 38, 38, 35, 40, 39)	-1.7 (± 9.1)	0.0 (± 7.5)		
SFU (4, 4, 4, 2, 1, 3)	-7.0 (± 999)	7.3 (± 3.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline until Safety Follow-up Visit in vital signs (temperature)

End point title	Change from Baseline until Safety Follow-up Visit in vital signs (temperature)

End point description:

Temperature was measured in degrees Celsius (°C).
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note 1: 999 is used as a placeholder for values not evaluable because only one participant was analyzed.
Note 2: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	42	40
Units: °C				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 43)	-0.07 (± 0.23)	-0.04 (± 0.22)	0.02 (± 0.30)	-0.11 (± 0.32)
Week 2 (42, 39, 41, 39, 42, 42)	0.00 (± 0.26)	0.02 (± 0.26)	0.01 (± 0.33)	0.01 (± 0.35)
Week 4 (42, 39, 41, 39, 41, 41)	-0.05 (± 0.29)	0.03 (± 0.24)	0.00 (± 0.42)	-0.04 (± 0.24)
Week 6 (40, 38, 38, 37, 40, 40)	-0.03 (± 0.29)	-0.02 (± 0.25)	-0.01 (± 0.22)	-0.06 (± 0.43)
Week 8 (39, 38, 38, 37, 40, 40)	0.01 (± 0.24)	-0.02 (± 0.28)	0.00 (± 0.33)	-0.03 (± 0.41)
Week 12 (39, 38, 38, 35, 40, 39)	0.10 (± 0.27)	0.00 (± 0.27)	0.06 (± 0.36)	-0.04 (± 0.28)
SFU (4, 4, 4, 2, 1, 3)	0.08 (± 0.22)	0.15 (± 0.33)	-0.03 (± 0.05)	0.10 (± 0.00)

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: °C				
arithmetic mean (standard deviation)				
Week 1 (42, 39, 42, 40, 43, 43)	-0.07 (± 0.30)	0.02 (± 0.35)		
Week 2 (42, 39, 41, 39, 42, 42)	-0.04 (± 0.36)	-0.01 (± 0.35)		
Week 4 (42, 39, 41, 39, 41, 41)	-0.03 (± 0.26)	-0.01 (± 0.41)		
Week 6 (40, 38, 38, 37, 40, 40)	-0.03 (± 0.38)	0.07 (± 0.24)		
Week 8 (39, 38, 38, 37, 40, 40)	0.00 (± 0.35)	0.02 (± 0.31)		
Week 12 (39, 38, 38, 35, 40, 39)	0.00 (± 0.33)	0.00 (± 0.30)		

SFU (4, 4, 4, 2, 1, 3)	0.10 (± 999)	0.43 (± 0.31)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with clinically significant physical examination abnormalities

End point title	Percentage of participants with clinically significant physical examination abnormalities

End point description:

The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status. Any clinically significant abnormal findings during the study were captured as adverse events.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

End point type	Secondary

End point timeframe:

At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)	23.8	7.7	11.6	10.0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)	9.3	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with clinically significant abnormal 12-Lead electrocardiogram (ECG) findings

End point title	Percentage of participants with clinically significant abnormal 12-Lead electrocardiogram (ECG) findings

End point description:

Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.
The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.

Note: The number of participants analyzed for each timepoint is presented in parentheses following this model (PBO, BKZ 64 mg Q4W, BKZ 160 mg Q4W, BKZ 160 mg w/ LD Q4W, BKZ 320 mg Q4W, BKZ 480 mg Q4W).

End point type	Secondary

End point timeframe:

Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)

End point values	Placebo (SS)	Bimekizumab 64 mg Q4W (SS)	Bimekizumab 160 mg Q4W (SS)	Bimekizumab 160 mg w/ LD Q4W (SS)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	42	39	43	40
Units: percentage of participants				
number (not applicable)				
Baseline (42, 39, 43, 40, 43, 43)	0	0	0	2.5
Week 2 (42, 39, 41, 39, 42, 42)	0	0	0	2.6
Week 4 (42, 39, 41, 39, 41, 41)	0	0	0	0
Week 6 (40, 38, 38, 36, 40, 40)	0	0	0	0
Week 12 (39, 38, 38, 34, 39, 39)	0	0	0	0
SFU (4, 4, 4, 2, 1, 3)	0	0	0	0

End point values	Bimekizumab 320 mg Q4W (SS)	Bimekizumab 480 mg Q4W (SS)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	43	43		
Units: percentage of participants				
number (not applicable)				
Baseline (42, 39, 43, 40, 43, 43)	0	0		
Week 2 (42, 39, 41, 39, 42, 42)	0	0		
Week 4 (42, 39, 41, 39, 41, 41)	0	0		
Week 6 (40, 38, 38, 36, 40, 40)	0	0		
Week 12 (39, 38, 38, 34, 39, 39)	0	0		
SFU (4, 4, 4, 2, 1, 3)	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) were collected from Baseline (Week 0) to End of Safety Follow-up (up to Week 28)

Adverse event reporting additional description:

It was pre-specified to report AEs that have a start date on or following the first administration of treatment. TEAEs counts for each study period: Treatment Period (Wk1-12) for all participants who received at least 1 treatment and Post-Treatment Period for those who either enrolled in an extension study (PS0011) or entered a 20-week SFU Period.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.0

Reporting groups

Reporting group title	Placebo (SS) Treatment Period

Reporting group description:

During the Treatment Period participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).

Reporting group title	Bimekizumab 64 mg Q4W (SS) Treatment Period

Reporting group description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.

Reporting group title	Bimekizumab 160 mg Q4W (SS) Treatment Period

Reporting group description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.

Reporting group title	Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period

Reporting group description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.

Reporting group title	Bimekizumab 320 mg Q4W (SS) Treatment Period

Reporting group description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.

Reporting group title	Bimekizumab 480 mg Q4W (SS) Treatment Period

Reporting group description:

During the Treatment Period participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.

Reporting group title	Placebo (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive Placebo during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Reporting group title	Bimekizumab 64 mg Q4W (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive 64 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-

Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Reporting group title	Bimekizumab 160 mg Q4W (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Reporting group title	Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Reporting group title	Bimekizumab 320 mg Q4W (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive 320 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Reporting group title	Bimekizumab 480 mg Q4W (SS) Post-Treatment Period

Reporting group description:

At Week 12, participants who were randomized to receive 480 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.
Participants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.

Serious adverse events	Placebo (SS) Treatment Period	Bimekizumab 64 mg Q4W (SS) Treatment Period	Bimekizumab 160 mg Q4W (SS) Treatment Period
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 42 (2.38%)	0 / 39 (0.00%)	0 / 43 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			

subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Large intestine polyp			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Meningitis viral			
subjects affected / exposed	1 / 42 (2.38%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period	Bimekizumab 320 mg Q4W (SS) Treatment Period	Bimekizumab 480 mg Q4W (SS) Treatment Period
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Large intestine polyp			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Meningitis viral

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo (SS) Post-Treatment Period	Bimekizumab 64 mg Q4W (SS) Post-Treatment Period	Bimekizumab 160 mg Q4W (SS) Post-Treatment Period
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 42 (0.00%)	1 / 39 (2.56%)	0 / 43 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	0 / 42 (0.00%)	1 / 39 (2.56%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Large intestine polyp			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Meningitis viral			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period	Bimekizumab 320 mg Q4W (SS) Post-Treatment Period	Bimekizumab 480 mg Q4W (SS) Post-Treatment Period
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)

number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

  Colon cancer

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac disorders

  Myocardial infarction

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders

  Large intestine polyp

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations

  Meningitis viral

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo (SS) Treatment Period	Bimekizumab 64 mg Q4W (SS) Treatment Period	Bimekizumab 160 mg Q4W (SS) Treatment Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 42 (19.05%)	16 / 39 (41.03%)	12 / 43 (27.91%)
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 39 (0.00%)	3 / 43 (6.98%)
occurrences (all)	1	0	3
Vascular disorders			
Hypertension			

subjects affected / exposed	3 / 42 (7.14%)	1 / 39 (2.56%)	1 / 43 (2.33%)
occurrences (all)	3	1	1

Nervous system disorders
Headache

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	0 / 43 (0.00%)
occurrences (all)	0	2	0

Blood and lymphatic system disorders
Neutropenia

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	0 / 43 (0.00%)
occurrences (all)	0	2	0

Leukopenia

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	0 / 43 (0.00%)
occurrences (all)	0	3	0

Gastrointestinal disorders
Vomiting

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	0 / 43 (0.00%)
occurrences (all)	0	2	0

Musculoskeletal and connective tissue disorders
Arthralgia

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	0 / 43 (0.00%)
occurrences (all)	0	2	0

Infections and infestations
Nasopharyngitis

subjects affected / exposed	2 / 42 (4.76%)	5 / 39 (12.82%)	3 / 43 (6.98%)
occurrences (all)	2	5	3

Upper respiratory tract infection

subjects affected / exposed	1 / 42 (2.38%)	5 / 39 (12.82%)	2 / 43 (4.65%)
occurrences (all)	1	5	3

Respiratory tract infection

subjects affected / exposed	1 / 42 (2.38%)	2 / 39 (5.13%)	1 / 43 (2.33%)
occurrences (all)	1	2	1

Tonsillitis

subjects affected / exposed	0 / 42 (0.00%)	2 / 39 (5.13%)	2 / 43 (4.65%)
occurrences (all)	0	3	2

Oral candidiasis

subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	1 / 42 (2.38%)	2 / 39 (5.13%)	1 / 43 (2.33%)
occurrences (all)	1	2	1

Non-serious adverse events	Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period	Bimekizumab 320 mg Q4W (SS) Treatment Period	Bimekizumab 480 mg Q4W (SS) Treatment Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 40 (30.00%)	14 / 43 (32.56%)	10 / 43 (23.26%)
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 40 (5.00%)	1 / 43 (2.33%)	0 / 43 (0.00%)
occurrences (all)	2	2	0
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 40 (2.50%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences (all)	1	0	1
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 40 (2.50%)	2 / 43 (4.65%)	0 / 43 (0.00%)
occurrences (all)	1	3	0
Leukopenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 43 (2.33%)	3 / 43 (6.98%)
occurrences (all)	1	3	5

Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	3 / 40 (7.50%)	6 / 43 (13.95%)	4 / 43 (9.30%)
occurrences (all)	3	6	5
Upper respiratory tract infection			
subjects affected / exposed	3 / 40 (7.50%)	2 / 43 (4.65%)	0 / 43 (0.00%)
occurrences (all)	3	2	0
Respiratory tract infection			
subjects affected / exposed	1 / 40 (2.50%)	1 / 43 (2.33%)	0 / 43 (0.00%)
occurrences (all)	1	1	0
Tonsillitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	1 / 40 (2.50%)	3 / 43 (6.98%)	0 / 43 (0.00%)
occurrences (all)	1	3	0
Rhinitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	1 / 43 (2.33%)
occurrences (all)	0	0	1

Non-serious adverse events	Placebo (SS) Post-Treatment Period	Bimekizumab 64 mg Q4W (SS) Post-Treatment Period	Bimekizumab 160 mg Q4W (SS) Post-Treatment Period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			

Neutropenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 39 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period	Bimekizumab 320 mg Q4W (SS) Post-Treatment Period	Bimekizumab 480 mg Q4W (SS) Post-Treatment Period
Total subjects affected by non-serious			

adverse events			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			

subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 43 (0.00%)	0 / 43 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 July 2016	Protocol Amendment 1, dated 08 Jul 2016, was implemented to make the following substantial changes: •Extended the timing of the Safety Follow Up (SFU) Visit to 20 weeks after the last dose of investigational medicinal product (IMP). •Removed references to legal representatives being able to provide consent on behalf of participants. Participants who lacked the capacity to consent were not included in the study. •Clarified the exclusion criterion regarding laboratory values. •Clarified that participants with any pustular psoriasis (ie, localized or generalized) were ineligible for study participation and that development of any form of pustular psoriasis (ie, localized or generalized) during the study would have resulted in withdrawal from the study. •Clarified the Hospital Anxiety and Depression Scale (HADS) thresholds for study eligibility in the Exclusion Criteria and for withdrawal of a participant in the Withdrawal Criteria. •Clarified withdrawal criteria regarding participants who developed illnesses that would have interfered with study participation and regarding the withdrawal of participants due to Adverse Events (AEs) and clinical laboratory values. •Clarified the timing of the optional study exit interview. •Clarified the AEs for special monitoring. •Provided additional detail and a reference for recording the severity of AEs. •Removed the requirement to test for alcohol in the potential drug-induced liver injury (PDILI) urine toxicology screen. •Clarified the subgroup analyses that were performed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

 None reported